ATE356824T1 - L-ribo-lna analoge - Google Patents

L-ribo-lna analoge

Info

Publication number: ATE356824T1
Authority: AT; Austria
Prior art keywords: ribo; compounds; lna analogue; lna; analogue
Prior art date: 1999-05-04

Application number

AT00925080T

Other languages

English (en)

Inventor

Jesper Wengel

Original Assignee

Santaris Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-04

Filing date

2000-05-04

Publication date

2007-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27220811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE356824(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-04 Application filed by Santaris Pharma As filed Critical Santaris Pharma As

2007-04-15 Application granted granted Critical

2007-04-15 Publication of ATE356824T1 publication Critical patent/ATE356824T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
239000002777 nucleoside Substances 0.000 abstract 1
-1 nucleoside compounds Chemical class 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT00925080T 1999-05-04 2000-05-04 L-ribo-lna analoge ATE356824T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA199900603		1999-05-04
DKPA199901225		1999-09-01
DKPA200000032		2000-01-11

Publications (1)

Publication Number	Publication Date
ATE356824T1 true ATE356824T1 (de)	2007-04-15

Family

ID=27220811

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00925080T ATE356824T1 (de)	1999-05-04	2000-05-04	L-ribo-lna analoge

Country Status (16)

Country	Link
US (1)	US7053207B2 (de)
EP (1)	EP1178999B1 (de)
JP (1)	JP2002543214A (de)
KR (1)	KR100782896B1 (de)
CN (2)	CN1349541A (de)
AT (1)	ATE356824T1 (de)
AU (1)	AU776362B2 (de)
CA (1)	CA2372085C (de)
DE (1)	DE60033927T2 (de)
DK (1)	DK1178999T3 (de)
ES (1)	ES2283298T3 (de)
HK (1)	HK1048322A1 (de)
IL (1)	IL145497A0 (de)
NZ (1)	NZ514348A (de)
PT (1)	PT1178999E (de)
WO (1)	WO2000066604A2 (de)

Families Citing this family (982)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7119184B2 (en) *	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
US7572582B2 (en) *	1997-09-12	2009-08-11	Exiqon A/S	Oligonucleotide analogues
ES2234563T5 (es) *	1999-02-12	2018-01-17	Daiichi Sankyo Company, Limited	Nuevos análogos de nucleósidos y oligonucleótidos
US6734291B2 (en)	1999-03-24	2004-05-11	Exiqon A/S	Synthesis of [2.2.1]bicyclo nucleosides
DE60029314T2 (de) *	1999-03-24	2007-07-12	Exiqon A/S	Verbesserte Synthese für -2.2.1. I Bicyclo-Nukleoside
IL149694A0 (en) *	1999-12-23	2002-11-10	Exiqon As	Therapeutic uses of lna-modified oligonucleotides
US8202979B2 (en)	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US6936467B2 (en)	2000-03-27	2005-08-30	University Of Delaware	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
EP1268768A2 (de)	2000-03-27	2003-01-02	University Of Delaware	Gezielte chromosomale genom-änderungen mit modifizierten einzelsträngigen oligonukleotiden
EP1414840A4 (de)	2001-03-27	2005-04-13	Univ Delaware	Genomics-anwendungen für modifizierte oligonukleotide
US20050148530A1 (en)	2002-02-20	2005-07-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en)	2001-05-18	2009-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
GB0114719D0 (en) *	2001-06-15	2001-08-08	Glaxo Group Ltd	Compound
US9261460B2 (en)	2002-03-12	2016-02-16	Enzo Life Sciences, Inc.	Real-time nucleic acid detection processes and compositions
CA2459347C (en)	2001-09-04	2012-10-09	Exiqon A/S	Locked nucleic acid (lna) compositions and uses thereof
EP1446503A2 (de)	2001-09-27	2004-08-18	University Of Delaware	Zusammensetzung und verfahren zur verbesserung der oligonukleotidgesteuerten veränderung von nukleinsäuresequenzen
US7468244B2 (en)	2001-09-27	2008-12-23	University Of Delaware	Polymorphism detection and separation
WO2003039523A2 (en) *	2001-11-05	2003-05-15	Exiqon A/S	OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
CA2471218A1 (en) *	2001-12-21	2003-07-24	Applera Corporation	Heteroconfigurational polynucleotide and methods of use
US20060009409A1 (en)	2002-02-01	2006-01-12	Woolf Tod M	Double-stranded oligonucleotides
EP1572902B1 (de)	2002-02-01	2014-06-11	Life Technologies Corporation	HOCHWIRKSAME siRNAS ZUR REDUZIERUNG DER EXPRESSION VON ZIELGENEN
ATE556714T1 (de)	2002-02-01	2012-05-15	Life Technologies Corp	Doppelsträngige oligonukleotide
EP1432724A4 (de)	2002-02-20	2006-02-01	Sirna Therapeutics Inc	Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2003075856A2 (en)	2002-03-07	2003-09-18	University Of Delaware	Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
US9353405B2 (en)	2002-03-12	2016-05-31	Enzo Life Sciences, Inc.	Optimized real time nucleic acid detection processes
CA2480673A1 (en) *	2002-03-29	2003-10-09	Genentech, Inc.	Methods and compositions for detection and quantitation of nucleic acid analytes
AU2003225495B2 (en)	2002-04-05	2009-01-15	Roche Innovation Center Copenhagen A/S	Oligomeric compounds for the modulation HIF-1alpha expression
US7569575B2 (en)	2002-05-08	2009-08-04	Santaris Pharma A/S	Synthesis of locked nucleic acid derivatives
AU2003222743B2 (en) *	2002-05-08	2008-12-11	Roche Innovation Center Copenhagen A/S	Synthesis of locked nucleic acid derivatives
GB2406169B (en) *	2002-06-12	2006-11-01	Ambion Inc	Methods and compositions relating to labeled rna molecules that reduce gene expression
US20100075423A1 (en) *	2002-06-12	2010-03-25	Life Technologies Corporation	Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20040248094A1 (en) *	2002-06-12	2004-12-09	Ford Lance P.	Methods and compositions relating to labeled RNA molecules that reduce gene expression
US7005265B1 (en)	2002-06-20	2006-02-28	Wenhong Fan	Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays
US20040219565A1 (en)	2002-10-21	2004-11-04	Sakari Kauppinen	Oligonucleotides useful for detecting and analyzing nucleic acids of interest
WO2004046160A2 (en) *	2002-11-18	2004-06-03	Santaris Pharma A/S	Amino-lna, thio-lna and alpha-l-oxy-ln
AU2013201763B2 (en) *	2002-11-18	2015-05-07	Roche Innovation Center Copenhagen A/S	Amino-LNA, thio-LNA and alpha-L-oxy-LN
EP1426448A1 (de) *	2002-12-03	2004-06-09	bioMérieux BV	Methode zur Reduktion des Effektes von Sequenzvariationen in einem diagnostischen Hybridisierungsverfahren, Sonde zur Verwendung in einem solchen Verfahren, sowie das Verfahren selbst
US20060292438A1 (en) *	2002-12-23	2006-12-28	Applera Corporation; Applied Biosystems Group	Heteroconfigurational Polynucleotides and Methods of Use
US7713738B2 (en)	2003-02-10	2010-05-11	Enzon Pharmaceuticals, Inc.	Oligomeric compounds for the modulation of survivin expression
DK1592793T3 (da)	2003-02-10	2009-10-26	Santaris Pharma As	Oligomeriske forbindelser for modulation af Survivin ekspression
ATE443765T1 (de)	2003-03-21	2009-10-15	Santaris Pharma As	Analoga kurzer interferierender rna (sirna)
WO2004106356A1 (en) *	2003-05-27	2004-12-09	Syddansk Universitet	Functionalized nucleotide derivatives
CN1833034B (zh) *	2003-06-20	2014-04-16	埃克斯魁恩公司	用于分析核酸混合物的探针、文库和试剂盒及其构建方法
US7683036B2 (en) *	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US8969314B2 (en)	2003-07-31	2015-03-03	Regulus Therapeutics, Inc.	Methods for use in modulating miR-122a
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US7480382B2 (en) *	2003-09-30	2009-01-20	Microsoft Corporation	Image file container
WO2005045033A1 (ja) *	2003-11-07	2005-05-19	Sankyo Company, Limited	遺伝子多型の検出方法
WO2005061710A1 (en)	2003-12-23	2005-07-07	Santaris Pharma A/S	Oligomeric compounds for the modulation of bcl-2
GB0406864D0 (en)	2004-03-26	2004-04-28	Qiagen As	Nucleic acid sequencing
US8192937B2 (en)	2004-04-07	2012-06-05	Exiqon A/S	Methods for quantification of microRNAs and small interfering RNAs
EP1747022A4 (de)	2004-04-23	2010-03-31	Univ Columbia	Hemmung von haarloser protein mrna
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP2290073A3 (de)	2004-05-28	2011-08-31	Asuragen, Inc.	Verfahren und Zusammensetzungen mit MicroRNA
WO2006050732A2 (en)	2004-11-09	2006-05-18	Santaris Pharma A/S	Lna oligonucleotides and the treatment of cancer
CN101065485B (zh) *	2004-11-09	2011-12-07	桑塔里斯制药公司	Lna寡核苷酸和癌症治疗
MX2007005558A (es)	2004-11-09	2008-01-31	Santaris Pharma As	Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a.
US9447138B2 (en)	2004-11-09	2016-09-20	Roche Innovation Center Copenhagen A/S	Potent LNA oligonucleotides for the inhibition of HIF-1a expression
EP2302055B1 (de)	2004-11-12	2014-08-27	Asuragen, Inc.	Verfahren und Zusammensetzungen, die miRNAs und miRNAa-inhibitorischen Molekülen verbunden sind
US20060166238A1 (en) *	2004-12-22	2006-07-27	Ramsing Niels B	Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
US20060142228A1 (en) *	2004-12-23	2006-06-29	Ambion, Inc.	Methods and compositions concerning siRNA's as mediators of RNA interference
EP1838870A2 (de)	2004-12-29	2007-10-03	Exiqon A/S	Neue oligonukleotidzusammensetzungen und sondensequenzen mit eignung zum nachweis und zur analyse von micrornas und ihren ziel-mrnas
EP1855694B1 (de)	2005-02-09	2020-12-02	Sarepta Therapeutics, Inc.	Antisense-zusammensetzung zur behandlung von muskelatrophie
JP2008537551A (ja)	2005-03-31	2008-09-18	カランドファーマシューティカルズ，インコーポレイテッド	リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
US7838502B2 (en)	2005-05-06	2010-11-23	University Of Massachusetts Medical School	Compositions and methods to modulate H. influenzae pathogenesis
EP3470072A1 (de)	2005-06-23	2019-04-17	Biogen MA Inc.	Zusammensetzungen und verfahren zur modulation der smn2-spleissung
EP1915461B1 (de)	2005-08-17	2018-08-01	Dx4U GmbH	Zusammensetzung und verfahren zur bestimmung der ck19-expression
US20070054872A1 (en) *	2005-08-24	2007-03-08	Mirus Bio Corporation	Regulatable or conditional expression systems
EP1931780B1 (de)	2005-08-29	2016-01-06	Regulus Therapeutics Inc.	Antisense-verbindungen mit verbesserter anti-mikrorna-aktivität
ES2548240T3 (es)	2005-12-01	2015-10-15	Pronai Therapeutics, Inc.	Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
WO2007073149A1 (en)	2005-12-22	2007-06-28	Keygene N.V.	Alternative nucleotides for improved targeted nucleotide exchange
JP5713377B2 (ja)	2005-12-28	2015-05-07	ザスクリプスリサーチインスティテュート	薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
PT1981902E (pt)	2006-01-27	2015-11-02	Biogen Ma Inc	Antagonistas dos recetores nogo
AU2007211082B2 (en)	2006-01-27	2012-09-27	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of microRNAs
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
WO2007090071A2 (en)	2006-01-27	2007-08-09	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
WO2007107162A2 (en)	2006-03-23	2007-09-27	Santaris Pharma A/S	Small internally segmented interfering rna
SG10201406016SA (en)	2006-04-03	2014-11-27	Stella Aps	Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2007888A2 (de)	2006-04-03	2008-12-31	Santaris Pharma A/S	Pharmazeutische zusammensetzung mit anti-mirna-antisense-oligonukleotiden
EP2505648A1 (de)	2006-05-05	2012-10-03	Isis Pharmaceuticals, Inc.	Verbindungen und Verfahren zur Modulation der Expression von PTP1B
JP2009536222A (ja)	2006-05-05	2009-10-08	アイシスファーマシューティカルズ，インコーポレーテッド	Ｐｃｓｋ９の発現を調節するための化合物および方法
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) *	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
EP2054415A1 (de) *	2006-07-14	2009-05-06	Santaris Pharma A/S	Adenosinrezeptorantagonisten
ES2526295T5 (es)	2006-10-18	2021-05-04	Ionis Pharmaceuticals Inc	Compuestos antisentido
EP2090665A2 (de)	2006-10-20	2009-08-19	Exiqon A/S	Neue humane MikroRNAs im Zusammenhang mit Krebs
US8188255B2 (en)	2006-10-20	2012-05-29	Exiqon A/S	Human microRNAs associated with cancer
WO2008052774A2 (en)	2006-10-31	2008-05-08	Noxxon Pharma Ag	Methods for detection of a single- or double-stranded nucleic acid molecule
EP2094832B1 (de)	2006-11-15	2015-04-22	The J. David Gladstone Institutes	Verfahren und zusammensetzungen zur verringerung von amyloid-beta-spiegeln
CA2670563A1 (en) *	2006-11-27	2008-06-05	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
EP3536788A1 (de)	2006-12-21	2019-09-11	QIAGEN GmbH	Mikro-rna-zielortblockierende oligos und verwendungen davon
WO2008086807A2 (en)	2007-01-19	2008-07-24	Exiqon A/S	Mediated cellular delivery of lna oligonucleotides
WO2009045469A2 (en)	2007-10-02	2009-04-09	Amgen Inc.	Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
US20080206850A1 (en) *	2007-02-28	2008-08-28	Dellinger Douglas J	Methods and compositions for DNA synthesis
US8470791B2 (en)	2007-03-22	2013-06-25	Santaris Pharma A/S	RNA antagonist compounds for the inhibition of Apo-B100 expression
DK2149605T3 (da)	2007-03-22	2013-09-30	Santaris Pharma As	Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
US8999634B2 (en)	2007-04-27	2015-04-07	Quest Diagnostics Investments Incorporated	Nucleic acid detection combining amplification with fragmentation
CA2688321A1 (en)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocyclic bicyclic nukleinsyreanaloge
WO2008151631A2 (en) *	2007-06-15	2008-12-18	Exiqon A/S	Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
AU2008272918B2 (en) *	2007-07-05	2012-09-13	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
WO2009036332A1 (en)	2007-09-14	2009-03-19	Asuragen, Inc.	Micrornas differentially expressed in cervical cancer and uses thereof
EP2195428B1 (de)	2007-09-19	2013-12-11	Applied Biosystems, LLC	Sirna-sequenz-unabhängige modifikationsformate zur verringerung von das ziel verfehlenden phänotypischen effekten bei rnai und stabilisierte formen davon
EP2623599B1 (de)	2007-10-04	2019-01-02	Roche Innovation Center Copenhagen A/S	Mikromir-Moleküle
WO2009067647A1 (en) *	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Carbocyclic alpha-l-bicyclic nucleic acid analogs
EP4053546A1 (de)	2007-12-06	2022-09-07	Genalyte, Inc.	Vorrichtung und verfahren zur kennzeichnungsfreien überwachung von prozessen.
CA2708751A1 (en)	2007-12-14	2009-06-25	Minitube Of America, Inc.	Gender-specific separation of sperm cells and embryos
WO2009100320A2 (en) *	2008-02-07	2009-08-13	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
CA2717792A1 (en)	2008-03-07	2009-09-11	Santaris Pharma A/S	Pharmaceutical compositions for treatment of microrna related diseases
US8227431B2 (en)	2008-03-17	2012-07-24	Hetero Drugs Limited	Nucleoside derivatives
EP2274423A2 (de) *	2008-04-04	2011-01-19	Isis Pharmaceuticals, Inc.	Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
AU2009232355A1 (en)	2008-04-04	2009-10-08	Calando Pharmaceuticals, Inc.	Compositions and use of EPAS1 inhibitors
US9290534B2 (en) *	2008-04-04	2016-03-22	Ionis Pharmaceuticals, Inc.	Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
WO2009137807A2 (en)	2008-05-08	2009-11-12	Asuragen, Inc.	Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US8222221B2 (en)	2008-06-04	2012-07-17	The Board Of Regents Of The University Of Texas System	Modulation of gene expression through endogenous small RNA targeting of gene promoters
CA2635187A1 (en)	2008-06-05	2009-12-05	The Royal Institution For The Advancement Of Learning/Mcgill University	Oligonucleotide duplexes and uses thereof
CA2732343C (en)	2008-07-29	2017-05-09	The Board Of Regents Of The University Of Texas System	Selective inhibition of polyglutamine protein expression
WO2010012667A1 (en)	2008-08-01	2010-02-04	Santaris Pharma A/S	Micro-rna mediated modulation of colony stimulating factors
EP2323667A4 (de) *	2008-08-07	2012-07-25	Isis Pharmaceuticals Inc	Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
DK2356129T3 (da) *	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
CN102239260B (zh) *	2008-10-03	2017-04-12	库尔纳公司	通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
KR101773551B1 (ko)	2008-10-15	2017-08-31	아이오니스 파마수티컬즈, 인코포레이티드	인자 １１ 발현의 조정
EP2447274B1 (de)	2008-10-24	2017-10-04	Ionis Pharmaceuticals, Inc.	Oligomerverbindungen und Verfahren
EP3572796B8 (de)	2008-10-27	2023-01-18	Genalyte, Inc.	Biosensoren basierend auf optischer sondierung und abtastung
ES2600781T3 (es)	2008-12-04	2017-02-10	Curna, Inc.	Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
ES2629630T3 (es)	2008-12-04	2017-08-11	Curna, Inc.	Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
US20110294870A1 (en)	2008-12-04	2011-12-01	Opko Curna, Llc	Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
US20110312094A1 (en)	2008-12-22	2011-12-22	Keygene N.V.	Use of double stranded rna to increase the efficiency of targeted gene alteration in plant protoplasts
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
ES2762610T3 (es)	2009-02-12	2020-05-25	Curna Inc	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
CN102482677B (zh)	2009-03-16	2017-10-17	库尔纳公司	通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
WO2010107740A2 (en)	2009-03-17	2010-09-23	Curna, Inc.	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
ES2599979T3 (es)	2009-04-24	2017-02-06	Roche Innovation Center Copenhagen A/S	Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
WO2010124231A2 (en)	2009-04-24	2010-10-28	The Board Of Regents Of The University Of Texas System	Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
ES2609655T3 (es)	2009-05-06	2017-04-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
CN103223177B (zh)	2009-05-06	2016-08-10	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
JP5931720B2 (ja)	2009-05-08	2016-06-08	クルナ・インコーポレーテッド	Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
DK2432881T3 (en)	2009-05-18	2018-02-26	Curna Inc	TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
CA2762987A1 (en)	2009-05-22	2010-11-25	Joseph Collard	Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
KR101704988B1 (ko)	2009-05-28	2017-02-08	큐알엔에이, 인크.	항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
WO2010141511A2 (en)	2009-06-01	2010-12-09	Halo-Bio Rnai Therapeutics, Inc.	Polynucleotides for multivalent rna interference, compositions and methods of use thereof
US8951981B2 (en)	2009-06-16	2015-02-10	Curna, Inc.	Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
WO2010148050A2 (en)	2009-06-16	2010-12-23	Curna, Inc.	Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2699827T3 (es)	2009-06-17	2019-02-13	Biogen Ma Inc	Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
WO2010151671A2 (en)	2009-06-24	2010-12-29	Curna, Inc.	Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2446037B1 (de)	2009-06-26	2016-04-20	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
EP2456870A1 (de)	2009-07-21	2012-05-30	Santaris Pharma A/S	Auf pcsk9 gerichtete antisense-oligomere
CN102712925B (zh)	2009-07-24	2017-10-27	库尔纳公司	通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
CN102762731B (zh)	2009-08-05	2018-06-22	库尔纳公司	通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
US9012421B2 (en)	2009-08-06	2015-04-21	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
CN104313027B (zh)	2009-08-11	2018-11-20	库尔纳公司	通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
KR101805213B1 (ko)	2009-08-21	2017-12-06	큐알엔에이, 인크.	Ｃｈｉｐ에 대한 천연 안티센스 전사체의 억제에 의한 “ｈｓｐ70-상호작용 단백질(ｃｈｉｐ)의 ｃ-말단” 관련된 질환의 치료
CA2771172C (en)	2009-08-25	2021-11-30	Opko Curna, Llc	Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
US20110196141A1 (en) *	2009-09-07	2011-08-11	Council Of Scientific & Industrial Research	Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides
WO2011032034A2 (en)	2009-09-10	2011-03-17	University Of Idaho	Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids
US20120295952A1 (en)	2009-09-25	2012-11-22	Curna, Inc.	Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
SI2493922T1 (sl)	2009-10-26	2017-06-30	F. Hoffmann-La Roche Ag	Postopek za proizvodnjo glikoziliranega imunoglobulina
US20110110860A1 (en)	2009-11-02	2011-05-12	The Board Of Regents Of The University Of Texas System	Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
EP2499248B1 (de)	2009-11-13	2017-01-04	Sarepta Therapeutics, Inc.	Antivirale antisense-verbindung und verfahren zur behandlung von influenzavirusinfektion
JP6025567B2 (ja)	2009-12-16	2016-11-16	カッパーアールエヌエー，インコーポレイテッド	膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療
CN102869776B (zh)	2009-12-23	2017-06-23	库尔纳公司	通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
RU2619185C2 (ru)	2009-12-23	2017-05-12	Курна, Инк.	Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
EP2519633B1 (de)	2009-12-29	2017-10-25	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem nuclear-respirator-faktor 1 (nrf1) mittels hemmung des natürlichen antisense-transkripts gegen nrf1
ES2585829T3 (es)	2009-12-29	2016-10-10	Curna, Inc.	Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
CA2785727C (en)	2009-12-31	2020-01-07	Curna, Inc.	Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
CA2785832A1 (en)	2010-01-04	2011-07-07	Curna, Inc.	Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
KR101853509B1 (ko)	2010-01-06	2018-04-30	큐알엔에이, 인크.	췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
CN102753186B (zh)	2010-01-08	2016-09-14	Isis制药公司	血管生成素样3表达的调节
JP6027893B2 (ja)	2010-01-11	2016-11-16	カッパーアールエヌエー，インコーポレイテッド	性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011088148A1 (en) *	2010-01-12	2011-07-21	Isis Pharmaceuticals, Inc.	Modulation of transforming growth factor-beta 1 expression
EP2529015B1 (de)	2010-01-25	2017-11-15	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit rnase h1 mittels hemmung des natürlichen antisense-transkripts gegen rnase h1
WO2011097388A1 (en)	2010-02-03	2011-08-11	Alnylam Pharmaceuticals, Inc.	Selective inhibition of polyglutamine protein expression
US8957040B2 (en)	2010-02-08	2015-02-17	Isis Pharmaceuticals, Inc.	Selective reduction of allelic variants
CA2789038A1 (en)	2010-02-08	2011-08-11	Isis Pharmaceuticals, Inc.	Selective reduction of allelic variants
CN102844435B (zh)	2010-02-22	2017-05-10	库尔纳公司	通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
US20110213011A1 (en) *	2010-02-26	2011-09-01	Dean Nicholas M	Modulation of smad3 expression
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
US9068185B2 (en)	2010-03-12	2015-06-30	Sarepta Therapeutics, Inc.	Antisense modulation of nuclear hormone receptors
EP3210611B1 (de)	2010-03-12	2019-08-21	The Brigham and Women's Hospital, Inc.	Verfahren zur behandlung von gefässentzündungserkrankungen
US9193752B2 (en)	2010-03-17	2015-11-24	Isis Pharmaceuticals, Inc.	5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
RU2612884C2 (ru)	2010-04-02	2017-03-13	Курна, Инк.	Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
EP2555778A4 (de)	2010-04-06	2014-05-21	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur hemmung der cd274/pd-l1-genexpression
WO2011127337A2 (en)	2010-04-09	2011-10-13	Opko Curna Llc	Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
CA2797093C (en)	2010-04-26	2019-10-29	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (de)	2010-04-27	2017-08-09	aTyr Pharma, Inc.	Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von isoleucyl-trna-synthetasen
CN103097524B (zh)	2010-04-28	2016-08-03	Atyr医药公司	与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011139699A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
EP2601204B1 (de)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modifizierte nukleoside und daraus hergestellte oligomere verbindungen
EP2563383B1 (de)	2010-04-29	2017-03-01	Atyr Pharma, Inc.	Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
CA2797374C (en)	2010-04-29	2021-02-16	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
US20130156845A1 (en)	2010-04-29	2013-06-20	Alnylam Pharmaceuticals, Inc.	Lipid formulated single stranded rna
PL2563920T3 (pl)	2010-04-29	2017-08-31	Ionis Pharmaceuticals, Inc.	Modulacja ekspresji transtyretyny
ES2465948T3 (es)	2010-04-30	2014-06-09	Exiqon A/S	Procedimiento de hibridación in situ y tampón
ES2668207T3 (es)	2010-05-03	2018-05-17	Atyr Pharma, Inc.	Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
AU2011248227B2 (en)	2010-05-03	2016-12-01	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CN103096925A (zh)	2010-05-03	2013-05-08	Atyr医药公司	与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008844B2 (ja)	2010-05-04	2016-10-19	エータイアーファーマ，インコーポレイテッド	ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA3090304A1 (en)	2010-05-13	2011-11-17	Sarepta Therapeutics, Inc.	Antisense modulation of interleukins 17 and 23 signaling
EP2568996B1 (de)	2010-05-14	2017-10-04	aTyr Pharma, Inc.	Therapeutische, diagnostische und antikörperhaltige zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US9034598B2 (en)	2010-05-17	2015-05-19	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
ES2664585T3 (es)	2010-05-26	2018-04-20	Curna, Inc.	Tratamiento de enfermedades relacionadas con metionina sulfóxido reductasa (MSRA) mediante inhibición del transcrito antisentido natural a MSRA
US8895528B2 (en)	2010-05-26	2014-11-25	Curna, Inc.	Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
CN103096913B (zh)	2010-05-27	2017-07-18	Atyr 医药公司	与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA3102008A1 (en)	2010-06-02	2011-12-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
US8957200B2 (en)	2010-06-07	2015-02-17	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2580228B1 (de)	2010-06-08	2016-03-23	Ionis Pharmaceuticals, Inc.	Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
US9518259B2 (en)	2010-06-15	2016-12-13	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating interaction between proteins and target nucleic acids
CN109112126B (zh)	2010-06-23	2024-06-14	库尔纳公司	通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
AU2011289831C1 (en)	2010-07-12	2017-06-15	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
JP5998131B2 (ja)	2010-07-14	2016-09-28	カッパーアールエヌエー，インコーポレイテッド	Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
EP2595663A4 (de)	2010-07-19	2014-03-05	Isis Pharmaceuticals Inc	Modulation der dystrophia-myotonica-proteinkinase (dmpk)-expression
US9243246B2 (en)	2010-08-24	2016-01-26	Sirna Therapeutics, Inc.	Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
CN103108650A (zh)	2010-08-25	2013-05-15	Atyr医药公司	与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2616555B1 (de)	2010-09-16	2017-11-08	Gen-Probe Incorporated	Über l-nukleotidenden immobilisierbare fängersonden
EP2619215B1 (de)	2010-09-22	2018-09-05	Alios Biopharma, Inc.	Azido-nukleoside und nukleotidanaloga
CN103210086B (zh)	2010-10-06	2017-06-09	库尔纳公司	通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
EP2625292B1 (de)	2010-10-07	2018-12-05	The General Hospital Corporation	Krebsbiomarker
US8648053B2 (en)	2010-10-20	2014-02-11	Rosalind Franklin University Of Medicine And Science	Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
KR101865433B1 (ko)	2010-10-22	2018-07-13	큐알엔에이, 인크.	알파-l 이두로니다아제 (idua)에 대한 자연 안티센스 전사체의 저해에 의한 idua 관련된 질환의 치료
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2635710B1 (de)	2010-11-05	2017-08-09	Genalyte, Inc.	Optische analytnachweissysteme und anwendungsverfahren dafür
US9150864B2 (en)	2010-11-08	2015-10-06	Isis Pharmaceuticals, Inc.	Methods for modulating factor 12 expression
CA2817256A1 (en)	2010-11-12	2012-05-18	The General Hospital Corporation	Polycomb-associated non-coding rnas
CA2817960C (en)	2010-11-17	2020-06-09	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
US10000752B2 (en)	2010-11-18	2018-06-19	Curna, Inc.	Antagonat compositions and methods of use
WO2012071238A2 (en)	2010-11-23	2012-05-31	Opko Curna Llc	Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
EP2857512B1 (de)	2010-12-02	2016-06-29	Keygene N.V.	Gezielte Änderung von DNA
DK2646550T3 (en)	2010-12-02	2015-05-26	Keygene Nv	Targeted DNA modification with oligonucleotides
EP2648763A4 (de)	2010-12-10	2014-05-14	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
EP2649182A4 (de)	2010-12-10	2015-05-06	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
EP2663323B1 (de)	2011-01-14	2017-08-16	The General Hospital Corporation	Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
EP2673361B1 (de)	2011-02-08	2016-04-13	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und ihre verwendung
PH12013501969B1 (en)	2011-03-29	2018-08-31	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of tmprss6 gene
CN103562215B (zh)	2011-04-01	2017-04-26	埃西斯药品公司	信号转导及转录激活蛋白3(stat3)表达的调节
CN103547588B (zh)	2011-04-13	2016-06-29	Isis制药公司	Ptp1b表达的反义调节
RS61447B1 (sr)	2011-04-21	2021-03-31	Glaxo Group Ltd	Modulacija ekspresije virusa hepatitisa b (hbv)
SG194671A1 (en)	2011-04-27	2013-12-30	Isis Pharmaceuticals Inc	Modulation of apolipoprotein ciii (apociii) expression
US9353371B2 (en)	2011-05-02	2016-05-31	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
KR102043422B1 (ko)	2011-06-09	2019-11-11	큐알엔에이, 인크.	프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료
EP3320922A1 (de)	2011-06-10	2018-05-16	Ionis Pharmaceuticals, Inc.	Verfahren zur modulierung der kallikrein (klkb1)-expression
WO2012170947A2 (en)	2011-06-10	2012-12-13	Isis Pharmaceuticals, Inc.	Methods for modulating factor 12 expression
JP6043347B2 (ja)	2011-06-16	2016-12-14	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	線維芽細胞増殖因子受容体４の発現のアンチセンス調節
EP2723758B1 (de)	2011-06-21	2018-06-20	Alnylam Pharmaceuticals, Inc.	Angiopoietin-3 (angptl3)-irna-zusammensetzungen und verwendungsverfahren dafür
WO2012178033A2 (en)	2011-06-23	2012-12-27	Alnylam Pharmaceuticals, Inc.	Serpina1 sirnas: compositions of matter and methods of treatment
US9322021B2 (en)	2011-06-29	2016-04-26	Ionis Pharmaceuticals, Inc.	Methods for modulating kallikrein (KLKB1) expression
US10100305B2 (en)	2011-07-15	2018-10-16	Sarepta Therapeutics, Inc.	Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites
BR112014001075A2 (pt)	2011-07-19	2016-11-29	Univ Idaho	sonda, seu uso, método in vitro para associar uma sonda com um alvo e kit
EP2739735A2 (de)	2011-08-01	2014-06-11	Alnylam Pharmaceuticals, Inc.	Verfahren zur verbesserung der erfolgsquote von hämatopoetischen stammzellentransplantaten
US10202599B2 (en)	2011-08-11	2019-02-12	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
WO2013033230A1 (en)	2011-08-29	2013-03-07	Isis Pharmaceuticals, Inc.	Oligomer-conjugate complexes and their use
WO2013033223A1 (en)	2011-08-29	2013-03-07	Isis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
MX365525B (es)	2011-09-06	2019-06-06	Curna Inc	Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
WO2013040251A2 (en)	2011-09-13	2013-03-21	Asurgen, Inc.	Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
WO2013043817A1 (en)	2011-09-20	2013-03-28	Isis Phamaceuticals, Inc.	Antisense modulation of gcgr expression
US20130085139A1 (en)	2011-10-04	2013-04-04	Royal Holloway And Bedford New College	Oligomers
US10184151B2 (en)	2011-10-11	2019-01-22	The Brigham And Women's Hospital, Inc.	Micrornas in neurodegenerative disorders
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
AU2012328680A1 (en)	2011-10-25	2014-05-01	Ionis Pharmaceuticals, Inc.	Antisense modulation of GCCR expression
WO2013067050A1 (en)	2011-10-31	2013-05-10	University Of Utah Research Foundation	Genetic alterations in glioblastoma
HRP20191883T1 (hr)	2011-11-07	2019-12-27	Ionis Pharmaceuticals, Inc.	Modulacija ekspresije tmprss6
US9243291B1 (en)	2011-12-01	2016-01-26	Isis Pharmaceuticals, Inc.	Methods of predicting toxicity
ES2935606T3 (es)	2011-12-08	2023-03-08	Sarepta Therapeutics Inc	Análogos de oligonucleótidos dirigidos a LMNA humana
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
AU2012358238B2 (en)	2011-12-22	2017-12-07	C. Frank Bennett	Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression
SG10201913554YA (en) *	2011-12-22	2020-03-30	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
EP2797948B1 (de)	2011-12-27	2019-02-20	The J. David Gladstone Institutes	Zusammensetzungen zur verwendung in der regulierung des glukosemetabolismus
EP2802674B1 (de)	2012-01-11	2020-12-16	Ionis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur modulation der ikbkap-aufspaltung
WO2013120003A1 (en)	2012-02-08	2013-08-15	Isis Pharmaceuticals, Inc.	Modulation of rna by repeat targeting
EP3907506A1 (de)	2012-03-12	2021-11-10	The Board of Trustees of the University of Illinois	Optische analytdetektionssysteme mit magnetischer verstärkung und verfahren zu deren verwendung
HK1210211A1 (en)	2012-03-15	2016-04-15	科纳公司	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9340784B2 (en)	2012-03-19	2016-05-17	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating alpha-1-antitrypsin expression
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
EP2831232A4 (de)	2012-03-30	2015-11-04	Univ Washington	Verfahren zur modulation der tau-expression zur verringerung von anfällen und modifizierung eines neurodegenerativen syndroms
CN104411338A (zh)	2012-04-02	2015-03-11	现代治疗公司	用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
WO2013151665A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins associated with human disease
WO2013154799A1 (en) *	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (de)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclische nukleinsäureanaloga
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013159108A2 (en)	2012-04-20	2013-10-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
WO2013163628A2 (en)	2012-04-27	2013-10-31	Duke University	Genetic correction of mutated genes
US9574193B2 (en)	2012-05-17	2017-02-21	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein (a) expression
US20160002624A1 (en)	2012-05-17	2016-01-07	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide compositions
WO2013177248A2 (en)	2012-05-22	2013-11-28	Isis Pharmaceuticals, Inc.	Modulation of enhancer rna mediated gene expression
EP3822352A3 (de)	2012-05-24	2021-11-03	Ionis Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur modulation der apolipoprotein(a)-expression
MX2014014323A (es)	2012-05-25	2015-02-12	Janssen R & D Ireland	Nucleosidos de espirooxetano de uracilo.
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
WO2014004572A2 (en)	2012-06-25	2014-01-03	Isis Pharmaceuticals, Inc.	Modulation of ube3a-ats expression
WO2014018930A1 (en)	2012-07-27	2014-01-30	Isis Pharmaceuticals. Inc.	Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
CN104736551B (zh)	2012-08-15	2017-07-28	Ionis制药公司	使用改进的封端方案制备寡聚化合物的方法
WO2014045126A2 (en)	2012-09-18	2014-03-27	Uti Limited Partnership	Treatment of pain by inhibition of usp5 de-ubiquitinase
US9695418B2 (en)	2012-10-11	2017-07-04	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
AR092982A1 (es)	2012-10-11	2015-05-13	Isis Pharmaceuticals Inc	Modulacion de la expresion de receptores androgenicos
EP4052709A1 (de)	2012-10-11	2022-09-07	Ionis Pharmaceuticals, Inc.	Verfahren zur behandlung der kennedy-krankheit
EP3459549B1 (de)	2012-10-12	2022-04-06	Ionis Pharmaceuticals, Inc.	Selektive antisense-verbindungen und verwendungen davon
EP2906255B1 (de)	2012-10-12	2023-02-22	Ionis Pharmaceuticals, Inc.	Antisense-verbindungen und verwendungen davon
EP2906697A4 (de)	2012-10-15	2016-06-22	Ionis Pharmaceuticals Inc	Verfahren zur überwachung der c9orf72-expression
CN104968783B (zh)	2012-10-15	2019-12-10	Ionis制药公司	用于调节c9orf72表达的组合物
ES2762326T5 (es)	2012-10-15	2023-04-27	Ionis Pharmaceuticals Inc	Métodos para modular la expresión de C9ORF72
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
HRP20190303T1 (hr)	2012-10-31	2019-05-17	Ionis Pharmaceuticals, Inc.	Liječenje raka
CA2890725A1 (en)	2012-11-05	2014-05-08	Pronai Therapeutics, Inc.	Methods of using biomarkers for the treatment of cancer by modulation of bcl2\|expression
US11230589B2 (en)	2012-11-05	2022-01-25	Foundation Medicine, Inc.	Fusion molecules and uses thereof
EP2914621B1 (de)	2012-11-05	2023-06-07	Foundation Medicine, Inc.	Neuartige ntrk1-fusionsmoleküle und verwendungen davon
CN104837996A (zh)	2012-11-15	2015-08-12	罗氏创新中心哥本哈根有限公司	抗apob反义缀合物化合物
WO2014080004A1 (en)	2012-11-26	2014-05-30	Santaris Pharma A/S	Compositions and methods for modulation of fgfr3 expression
PL2922554T3 (pl)	2012-11-26	2022-06-20	Modernatx, Inc.	Na zmodyfikowany na końcach
US9695475B2 (en)	2012-12-11	2017-07-04	Ionis Pharmaceuticals, Inc.	Competitive modulation of microRNAs
BR112015014457A2 (pt)	2012-12-21	2017-11-21	Alios Biopharma Inc	composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
WO2014110291A1 (en)	2013-01-09	2014-07-17	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of smn2 splicing in a subject
AU2013374345A1 (en)	2013-01-17	2015-08-06	Moderna Therapeutics, Inc.	Signal-sensor polynucleotides for the alteration of cellular phenotypes
CA3150658A1 (en)	2013-01-18	2014-07-24	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
AU2014211406B2 (en)	2013-01-30	2019-07-18	Roche Innovation Center Copenhagen A/S	LNA oligonucleotide carbohydrate conjugates
WO2014118272A1 (en)	2013-01-30	2014-08-07	Santaris Pharma A/S	Antimir-122 oligonucleotide carbohydrate conjugates
DK2951191T3 (en)	2013-01-31	2019-01-14	Ionis Pharmaceuticals Inc	PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS
WO2014121287A2 (en)	2013-02-04	2014-08-07	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
DK2956176T3 (en)	2013-02-14	2018-08-27	Ionis Pharmaceuticals Inc	MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
WO2014130922A1 (en)	2013-02-25	2014-08-28	Trustees Of Boston University	Compositions and methods for treating fungal infections
WO2014134179A1 (en)	2013-02-28	2014-09-04	The Board Of Regents Of The University Of Texas System	Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
WO2014134144A1 (en)	2013-02-28	2014-09-04	The General Hospital Corporation	Mirna profiling compositions and methods of use
EP2968391A1 (de)	2013-03-13	2016-01-20	Moderna Therapeutics, Inc.	Langlebige polynukleotidmoleküle
WO2014152211A1 (en)	2013-03-14	2014-09-25	Moderna Therapeutics, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
IL288931B2 (en)	2013-03-14	2025-05-01	Alnylam Pharmaceuticals Inc	Compositions comprising a complementary portion of C5 IRNA and methods of using them
CN105264091B (zh)	2013-03-14	2020-02-28	Ionis制药公司	用于调节tau表达的组合物和方法
US9273349B2 (en)	2013-03-14	2016-03-01	Affymetrix, Inc.	Detection of nucleic acids
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2014143637A1 (en)	2013-03-15	2014-09-18	The Board Of Trustees Of The University Of Illinois	Methods and compositions for enhancing immunoassays
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
US10590412B2 (en)	2013-04-19	2020-03-17	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
DK2992098T3 (da)	2013-05-01	2019-06-17	Ionis Pharmaceuticals Inc	Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
EA038792B1 (ru)	2013-05-22	2021-10-20	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR102234623B1 (ko)	2013-05-22	2021-04-02	알닐람 파마슈티칼스 인코포레이티드	Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
EP3004396B1 (de)	2013-06-06	2019-10-16	The General Hospital Corporation	Zusammensetzungen zur krebsbehandlung
EP3564374A1 (de)	2013-06-21	2019-11-06	Ionis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur modulation von zielnukleinsäuren
EP3011026B1 (de)	2013-06-21	2019-12-18	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation der apolipoprotein-c-iii-expression zur verbesserung eines diabetischen profils
HUE048738T2 (hu)	2013-06-27	2020-08-28	Roche Innovation Ct Copenhagen As	Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
CA2917229A1 (en)	2013-07-02	2015-01-08	Isis Pharmaceuticals, Inc.	Modulators of growth hormone receptor
CA2917348A1 (en)	2013-07-11	2015-01-15	Moderna Therapeutics, Inc.	Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
EP3022176B8 (de)	2013-07-15	2019-12-25	The Regents of the University of California	Eingeschränkte azacyclische analoga von fty720
TW202246503A (zh)	2013-07-19	2022-12-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
US10435430B2 (en)	2013-07-31	2019-10-08	Ionis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
HRP20200250T1 (hr)	2013-08-08	2020-05-29	The Scripps Research Institute	Metoda site-specifično enzimsko obilježavanje nukleinskih kiselina in vitro ugradnjom neprirodnih nukleotida
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
KR102365486B1 (ko)	2013-08-28	2022-02-18	아이오니스 파마수티컬즈, 인코포레이티드	프리칼리크레인 (pkk) 발현의 조절
EP3041934A1 (de)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Chimäre polynukleotide
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
US11236338B2 (en)	2013-09-05	2022-02-01	Sarepta Therapeutics, Inc.	Antisense-induced exon2 inclusion in acid alpha-glucosidase
MY181251A (en)	2013-09-13	2020-12-21	Ionis Pharmaceuticals Inc	Modulators of complement factor b
WO2015042447A1 (en)	2013-09-20	2015-03-26	Isis Pharmaceuticals, Inc.	Targeted therapeutic nucleosides and their use
CA2925107A1 (en)	2013-10-02	2015-04-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
EP3052521A1 (de)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
LT3052628T (lt)	2013-10-04	2020-09-10	Alnylam Pharmaceuticals, Inc.	Kompozicijos ir būdai alas1 geno raiškai nuslopinti
US10221414B2 (en)	2013-10-11	2019-03-05	Ionis Pharmaceuticals, Inc.	Compositions for modulating C9ORF72 expression
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
WO2015061246A1 (en)	2013-10-21	2015-04-30	Isis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
EP3683321B1 (de)	2013-10-21	2021-12-08	The General Hospital Corporation	Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und mit der behandlung von krebs
WO2015075166A1 (en)	2013-11-22	2015-05-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of a bacterial infection
DK3077510T3 (da)	2013-12-02	2020-06-08	Ionis Pharmaceuticals Inc	Antisense-forbindelser og anvendelser deraf
SG10201804960RA (en)	2013-12-12	2018-07-30	Alnylam Pharmaceuticals Inc	Complement component irna compositions and methods of use thereof
CN111729090A (zh)	2013-12-20	2020-10-02	通用医疗公司	与循环肿瘤细胞相关的方法和测定法
PT3087183T (pt)	2013-12-24	2020-10-08	Ionis Pharmaceuticals Inc	Modulação da expressão da proteína relacionada com angiopoietina 3
EP3099798B1 (de)	2014-01-29	2018-06-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Oligonukleotide und methoden zur inhibierung oder verminderung von bakteriellen biofilmen
CN113057959B (zh)	2014-02-11	2024-07-16	阿尔尼拉姆医药品有限公司	己酮糖激酶（KHK）iRNA组合物及其使用方法
EP3119789B1 (de)	2014-03-17	2020-04-22	Ionis Pharmaceuticals, Inc.	Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
US10006027B2 (en)	2014-03-19	2018-06-26	Ionis Pharmaceuticals, Inc.	Methods for modulating Ataxin 2 expression
EP3119888B1 (de)	2014-03-19	2021-07-28	Ionis Pharmaceuticals, Inc.	Zusammensetzungen zur modulierung der ataxin-2-expression
HUE050704T2 (hu)	2014-04-01	2020-12-28	Biogen Ma Inc	Összetételek a SOD-1 expressziójának modulálására
TWI638047B (zh)	2014-04-09	2018-10-11	史基普研究協會	藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
EP3797780B1 (de)	2014-04-17	2022-09-14	Biogen MA Inc.	Zusammensetzungen und verfahren zur modulation der smn2-aufspaltung in einem patienten
WO2015164693A1 (en)	2014-04-24	2015-10-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015168172A1 (en)	2014-04-28	2015-11-05	Isis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds
US10098959B2 (en)	2014-05-01	2018-10-16	Ionis Pharmaceuticals, Inc.	Method for synthesis of reactive conjugate clusters
HUE052709T2 (hu)	2014-05-01	2021-05-28	Ionis Pharmaceuticals Inc	Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
BR112016022742B1 (pt)	2014-05-01	2022-06-14	Ionis Pharmaceuticals, Inc	Composto químico, composição compreendendo o composto e uso dos mesmos
EA036496B1 (ru)	2014-05-01	2020-11-17	Ионис Фармасьютикалз, Инк.	Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
US9382540B2 (en)	2014-05-01	2016-07-05	Isis Pharmaceuticals, Inc	Compositions and methods for modulating angiopoietin-like 3 expression
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
AU2015264038B2 (en)	2014-05-22	2021-02-11	Alnylam Pharmaceuticals, Inc.	Angiotensinogen (AGT) iRNA compositions and methods of use thereof
WO2015179693A1 (en)	2014-05-22	2015-11-26	Isis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
EP3148564B1 (de)	2014-06-02	2020-01-08	Children's Medical Center Corporation	Verfahren und zusammensetzungen zur immunmodulation
GB201410693D0 (en)	2014-06-16	2014-07-30	Univ Southampton	Splicing modulation
EP3161159B1 (de)	2014-06-25	2020-08-05	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
US20170204152A1 (en)	2014-07-16	2017-07-20	Moderna Therapeutics, Inc.	Chimeric polynucleotides
EP3171895A1 (de)	2014-07-23	2017-05-31	Modernatx, Inc.	Modifizierte polynukleotide zur herstellung von intrabodys
CN107109474B (zh)	2014-08-19	2021-03-19	豪夫迈·罗氏有限公司	用于核酸检测的方法和组合物
CN107106704A (zh)	2014-08-29	2017-08-29	儿童医疗中心有限公司	用于治疗癌症的方法和组合物
WO2016040589A1 (en)	2014-09-12	2016-03-17	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
US10436802B2 (en)	2014-09-12	2019-10-08	Biogen Ma Inc.	Methods for treating spinal muscular atrophy
US11987836B2 (en) *	2014-09-30	2024-05-21	Global Life Sciences Solutions Usa Llc	Method for nucleic acid analysis directly from an unpurified biological sample
AU2015327836B2 (en)	2014-10-03	2021-07-01	Cold Spring Harbor Laboratory	Targeted augmentation of nuclear gene output
TW202503057A (zh)	2014-10-10	2025-01-16	美商艾爾妮蘭製藥公司	用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
WO2016061131A1 (en)	2014-10-14	2016-04-21	The J. David Gladstone Institutes	Compositions and methods for reactivating latent immunodeficiency virus
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3212794B1 (de)	2014-10-30	2021-04-07	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
KR102545316B1 (ko)	2014-11-10	2023-06-22	알닐람 파마슈티칼스 인코포레이티드	Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
CA2964979A1 (en)	2014-11-14	2016-05-19	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of proteins
WO2016077704A1 (en)	2014-11-14	2016-05-19	The Regents Of The University Of California	Modulation of agpat5 expression
JP2017535552A (ja)	2014-11-17	2017-11-30	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法
EP3221445B1 (de)	2014-11-20	2021-07-14	The Regents of The University of California	Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung
US10400243B2 (en)	2014-11-25	2019-09-03	Ionis Pharmaceuticals, Inc.	Modulation of UBE3A-ATS expression
WO2016094342A1 (en)	2014-12-08	2016-06-16	The Board Of Regents Of The University Of Texas System	Lipocationic polymers and uses thereof
EP3234134B1 (de)	2014-12-17	2020-05-27	ProQR Therapeutics II B.V.	Gezieltes rna-editing
JP2018504380A (ja)	2014-12-18	2018-02-15	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｒｅｖｅｒｓｉｒ（商標）化合物
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en)	2015-01-06	2020-10-06	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
US10538763B2 (en)	2015-01-16	2020-01-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of DUX4
WO2016130600A2 (en)	2015-02-09	2016-08-18	Duke University	Compositions and methods for epigenome editing
CA2976445A1 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
AU2016222546B2 (en)	2015-02-26	2020-01-23	Ionis Pharmaceuticals, Inc.	Allele specific modulators of P23H rhodopsin
US20180044673A1 (en)	2015-03-03	2018-02-15	Ionis Pharmaceuticals, Inc.	Methods for modulating mecp2 expression
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
WO2016141236A1 (en)	2015-03-03	2016-09-09	Ionis Pharmaceuticals, Inc.	Compositions for modulating mecp2 expression
MA41795A (fr)	2015-03-18	2018-01-23	Sarepta Therapeutics Inc	Exclusion d'un exon induite par des composés antisens dans la myostatine
MX2017012426A (es)	2015-04-03	2018-01-26	Ionis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de tmprss6.
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
US10745702B2 (en)	2015-04-08	2020-08-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
US10407678B2 (en)	2015-04-16	2019-09-10	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
RS60230B1 (sr)	2015-04-16	2020-06-30	Ionis Pharmaceuticals Inc	Kompozicije za moduliranje ekspresije c9orf72
MA50829A (fr)	2015-06-01	2018-04-11	Sarepta Therapeutics Inc	Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
WO2016201301A1 (en)	2015-06-12	2016-12-15	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (de)	2015-06-18	2020-08-05	Alnylam Pharmaceuticals, Inc.	Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
CN108139375A (zh)	2015-06-26	2018-06-08	贝斯以色列女执事医疗中心股份有限公司	靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
WO2017004261A1 (en)	2015-06-29	2017-01-05	Ionis Pharmaceuticals, Inc.	Modified crispr rna and modified single crispr rna and uses thereof
MX2018000412A (es)	2015-07-10	2018-03-14	Ionis Pharmaceuticals Inc	Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
CA3205381A1 (en)	2015-07-17	2017-01-26	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
EP3331536A4 (de)	2015-08-03	2019-03-27	The Regents of The University of California	Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
JP6835826B2 (ja)	2015-08-24	2021-02-24	ロシュイノベーションセンターコペンハーゲンエーエス	Ｌｎａ−ｇプロセス
WO2017035278A1 (en)	2015-08-24	2017-03-02	Halo-Bio Rnai Therapeutics, Inc.	Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
CA2996873A1 (en)	2015-09-02	2017-03-09	Alnylam Pharmaceuticals, Inc.	Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
WO2017048789A1 (en)	2015-09-14	2017-03-23	The Board Of Regents Of The University Of Texas System	Lipocationic dendrimers and uses thereof
WO2017048843A1 (en)	2015-09-14	2017-03-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the alas1 gene
CN108513588A (zh)	2015-09-24	2018-09-07	Ionis制药公司	Kras表达的调节剂
CA2999177A1 (en)	2015-09-24	2017-03-30	The Regents Of The University Of California	Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
EP4285912A3 (de)	2015-09-25	2024-07-10	Ionis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur modulation von ataxin 3-expression
CN113817735A (zh)	2015-10-08	2021-12-21	Ionis制药公司	用于调节血管紧张素原表达的化合物和方法
EP3858993A1 (de)	2015-10-09	2021-08-04	Sarepta Therapeutics, Inc.	Zusammensetzungen und verfahren zur behandlung von duchenne-muskeldystrophie und damit assoziierten erkrankungen
CN108603230A (zh)	2015-10-09	2018-09-28	南安普敦大学	基因表达的调节与蛋白质表达失调的筛选
EP4089175A1 (de)	2015-10-13	2022-11-16	Duke University	Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
WO2017068087A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide detection method
WO2017079291A1 (en)	2015-11-02	2017-05-11	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating c90rf72
PL4119569T3 (pl)	2015-11-06	2024-11-18	Ionis Pharmaceuticals, Inc.	Sprzężone związki antysensowne do zastosowania w terapii
KR20250078597A (ko)	2015-11-06	2025-06-02	아이오니스 파마수티컬즈, 인코포레이티드	아포리포프로테인 (a) 발현 조정
LT3374509T (lt)	2015-11-12	2021-03-10	F. Hoffmann-La Roche Ag	Oligonukleotidai, skirti sukelti iš tėvo paveldėto ube3a raišką
JP7027311B2 (ja)	2015-11-16	2022-03-01	オリックスファーマシューティカルズ，インコーポレーテッド	ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療
CA3005968A1 (en)	2015-11-23	2017-06-01	The Regents Of The University Of California	Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
KR102787119B1 (ko)	2015-11-30	2025-03-27	듀크 유니버시티	유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
EP3389670A4 (de)	2015-12-04	2020-01-08	Ionis Pharmaceuticals, Inc.	Verfahren zur behandlung von brustkrebs
KR20180095843A (ko)	2015-12-07	2018-08-28	젠자임 코포레이션	Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
US11096956B2 (en)	2015-12-14	2021-08-24	Stoke Therapeutics, Inc.	Antisense oligomers and uses thereof
WO2017106377A1 (en)	2015-12-14	2017-06-22	Cold Spring Harbor Laboratory	Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
PH12018501207B1 (en)	2015-12-21	2024-02-23	Novartis Ag	Compositions and methods for decreasing tau expression
AU2016381174A1 (en)	2015-12-31	2018-05-31	Ionis Pharmaceuticals, Inc.	Methods for reducing Ataxin-2 expression
CA3006599A1 (en)	2016-01-05	2017-07-13	Ionis Pharmaceuticals, Inc.	Methods for reducing lrrk2 expression
JP6944942B2 (ja)	2016-02-02	2021-10-06	オリックスファーマシューティカルズ，インコーポレーテッド	ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
JP7033072B2 (ja)	2016-02-25	2022-03-09	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	Ｓｍｏｃ２を標的化する線維症のための治療方法
WO2017156242A1 (en)	2016-03-09	2017-09-14	Ionis Pharmaceuticals, Inc.	Methods and compositions for inhibiting pmp22 expression
RU2747822C2 (ru)	2016-03-14	2021-05-14	Ф. Хоффманн-Ля Рош Аг	Олигонуклеотиды для понижения экспрессии pd-l1
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
EP3429690A4 (de)	2016-03-16	2019-10-23	Ionis Pharmaceuticals, Inc.	Verfahren zur modulation von keap1
US20190142856A1 (en)	2016-04-13	2019-05-16	Ionis Pharmaceuticals, Inc.	Methods for reducing c9orf72 expression
US20190127713A1 (en)	2016-04-13	2019-05-02	Duke University	Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
WO2017178656A1 (en)	2016-04-14	2017-10-19	Roche Innovation Center Copenhagen A/S	TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
WO2017184529A1 (en)	2016-04-18	2017-10-26	Sarepta Therapeutics, Inc.	Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
WO2017184689A1 (en)	2016-04-19	2017-10-26	Alnylam Pharmaceuticals, Inc.	High density lipoprotein binding protein (hdlbp/vigilin) irna compositions and methods of use thereof
US11390867B2 (en)	2016-04-29	2022-07-19	Nanyang Technological University	G-quadruplex-containing antisense oligonucleotides
MX2018013157A (es)	2016-04-29	2019-05-23	Sarepta Therapeutics Inc	Analogos de oligonucleotidos dirigidos a lmna humana.
WO2017192820A1 (en)	2016-05-06	2017-11-09	Ionis Pharmaceuticals, Inc.	Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
CN109414408B (zh)	2016-05-16	2022-03-29	得克萨斯州大学系统董事会	阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
US11472824B2 (en)	2016-05-24	2022-10-18	Sarepta Therapeutics, Inc.	Processes for preparing phosphorodiamidate morpholino oligomers
WO2017205506A1 (en)	2016-05-24	2017-11-30	Emory University	Particles with rna cleaving nucleobase polymers and uses for managing inflammatory disorders
BR112018074346B1 (pt)	2016-05-24	2023-01-03	Sarepta Therapeutics, Inc.	Composto oligomérico e processo para preparar um composto oligomérico
MD3464306T2 (ro)	2016-05-24	2024-08-31	Sarepta Therapeutics Inc	Procedee de preparare a oligomerilor morfolino fosforodiamidați
CA3024456A1 (en)	2016-05-24	2017-11-30	Sarepta Therapeutics, Inc.	Processes for preparing phosphorodiamidate morpholino oligomers
US10947533B2 (en)	2016-05-24	2021-03-16	Sarepta Therapeutics, Inc.	Processes for preparing phosphorodiamidate morpholino oligomers
EP3469083A1 (de)	2016-06-10	2019-04-17	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
US11198867B2 (en)	2016-06-16	2021-12-14	Ionis Pharmaceuticals, Inc.	Combinations for the modulation of SMN expression
EP4219767A1 (de)	2016-06-17	2023-08-02	F. Hoffmann-La Roche AG	Papd5- und papd7-inhibitoren zur behandlung einer hepatitis-b-infektion
AU2017286811A1 (en)	2016-06-17	2018-11-22	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
WO2017220751A1 (en)	2016-06-22	2017-12-28	Proqr Therapeutics Ii B.V.	Single-stranded rna-editing oligonucleotides
US20190218257A1 (en)	2016-06-24	2019-07-18	The Scripps Research Institute	Novel nucleoside triphosphate transporter and uses thereof
JP2019525742A (ja)	2016-06-30	2019-09-12	サレプタセラピューティクス，インコーポレイテッド	筋ジストロフィーに対するエクソンスキッピングオリゴマー
MX2018015722A (es)	2016-07-01	2019-05-27	Hoffmann La Roche	Oligonucleotidos antisentido para modular expresion del requisito de alta temperatura a 1 (htra1).
EP3484524B1 (de)	2016-07-15	2022-11-09	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation von smn2
JP7490211B2 (ja)	2016-07-19	2024-05-27	デュークユニバーシティ	Ｃｐｆ１に基づくゲノム編集の治療適用
WO2018017814A1 (en)	2016-07-20	2018-01-25	President And Fellows Of Harvard College	Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
CN110352244B (zh)	2016-09-01	2023-03-21	ProQR治疗上市公司Ⅱ	化学修饰的编辑rna的单链寡核苷酸
WO2018053142A2 (en)	2016-09-14	2018-03-22	President And Fellows Of Harvard College	Methods and compositions for modulating erythropoiesis
KR102533038B1 (ko)	2016-09-14	2023-05-17	얀센 바이오파마, 인크.	변형된 올리고뉴클레오티드 및 사용 방법
HUE065170T2 (hu)	2016-09-29	2024-05-28	Biogen Ma Inc	Vegyületek és módszerek a TAU expresszió csökkentésére
US11400161B2 (en)	2016-10-06	2022-08-02	Ionis Pharmaceuticals, Inc.	Method of conjugating oligomeric compounds
US11459568B2 (en)	2016-10-31	2022-10-04	University Of Massachusetts	Targeting microRNA-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
US20190284621A1 (en)	2016-11-11	2019-09-19	Roche Innovation Center Copenhagen A/S	Therapeutic oligonucleotides capture and detection
TWI788312B (zh)	2016-11-23	2023-01-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
WO2018102745A1 (en)	2016-12-02	2018-06-07	Cold Spring Harbor Laboratory	Modulation of lnc05 expression
WO2018112032A1 (en)	2016-12-13	2018-06-21	President And Fellows Of Harvard College	Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
WO2018112320A1 (en)	2016-12-16	2018-06-21	Alnylam Pharmaceuticals, Inc.	Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
KR20240006023A (ko)	2016-12-19	2024-01-12	사렙타 쎄러퓨틱스 인코퍼레이티드	근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
KR102810425B1 (ko)	2016-12-19	2025-05-21	사렙타 쎄러퓨틱스 인코퍼레이티드	근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
PT3554552T (pt)	2016-12-19	2022-10-03	Sarepta Therapeutics Inc	Conjugados de oligómero de skipping de exão para distrofia muscular
WO2018130584A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating nfkb2 expression
EP3568477A1 (de)	2017-01-13	2019-11-20	Roche Innovation Center Copenhagen A/S	Antisense-oligonukleotide zur modulierung der rela-expression
EP3568478A1 (de)	2017-01-13	2019-11-20	Roche Innovation Center Copenhagen A/S	Antisense-oligonukleotide zur modulierung der rel-expression
EP3568479A1 (de)	2017-01-13	2019-11-20	Roche Innovation Center Copenhagen A/S	Antisense-oligonukleotide zur modulierung der nfkb1-expression
US20190345496A1 (en)	2017-01-13	2019-11-14	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating relb expression
EP3571300A1 (de)	2017-01-19	2019-11-27	ProQR Therapeutics II B.V.	Oligonukleotidkomplexe zur verwendung bei der rna-editierung
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
JOP20190215A1 (ar)	2017-03-24	2019-09-19	Ionis Pharmaceuticals Inc	مُعدّلات التعبير الوراثي عن pcsk9
EP3609521A4 (de)	2017-04-14	2021-06-16	University of Massachusetts	Targeting von zelltropismus-rezeptoren zur hemmung von infektionen durch das cytomegalovirus
CA3059446A1 (en)	2017-04-18	2018-10-25	Alnylam Pharmaceuticals, Inc.	Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
CA3060514A1 (en)	2017-04-20	2018-10-25	Atyr Pharma, Inc.	Compositions and methods for treating lung inflammation
WO2018208998A1 (en)	2017-05-10	2018-11-15	The Regents Of The University Of California	Directed editing of cellular rna via nuclear delivery of crispr/cas9
US20190055564A1 (en)	2017-06-01	2019-02-21	F. Hoffmann-La Roche Ag	Antisense oligonucleotides for modulating htra1 expression
TW202434265A (zh)	2017-07-10	2024-09-01	美商健贊公司	於患有血友病之個體中治療出血事件之方法及組成物
WO2019014262A1 (en)	2017-07-11	2019-01-17	The Scripps Research Institute	INCORPORATION OF NON-NATURAL NUCLEOTIDES AND METHODS OF IN VIVO USE THEREOF
JP7325341B2 (ja)	2017-07-11	2023-08-14	シンソークス，インク．	非天然ヌクレオチドの組み込み及びその方法
KR20240141853A (ko)	2017-08-03	2024-09-27	신톡스, 인크.	자가면역 질환의 치료를 위한 사이토카인 접합체
WO2019030313A2 (en)	2017-08-11	2019-02-14	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
WO2019036613A1 (en)	2017-08-18	2019-02-21	Ionis Pharmaceuticals, Inc.	MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
WO2019038228A1 (en)	2017-08-22	2019-02-28	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
KR102318434B1 (ko)	2017-08-25	2021-11-01	스톡 테라퓨틱스, 인크.	병태 및 질환 치료용 안티센스 올리고머
US10517889B2 (en)	2017-09-08	2019-12-31	Ionis Pharmaceuticals, Inc.	Modulators of SMAD7 expression
EA202090720A1 (ru)	2017-09-14	2020-07-07	Янссен Байофарма, Инк.	ПРОИЗВОДНЫЕ GalNAc
EA201991450A1 (ru)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
WO2019067981A1 (en)	2017-09-28	2019-04-04	Sarepta Therapeutics, Inc.	POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
EP3687547A1 (de)	2017-09-28	2020-08-05	Sarepta Therapeutics, Inc.	Kombinationstherapien zur behandlung von muskeldystrophie
WO2019067979A1 (en)	2017-09-28	2019-04-04	Sarepta Therapeutics, Inc.	POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
EP3694995A1 (de)	2017-10-13	2020-08-19	Roche Innovation Center Copenhagen A/S	Verfahren zur identifizierung verbesserter stereodefinierter phosphorothioat-oligonukleotid-varianten von antisense-oligonukleotiden unter verwendung von unterbibliotheken von teilweise stereodefinierten oligonukleotiden
CN111511914B (zh)	2017-10-16	2023-11-17	豪夫迈·罗氏有限公司	减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
WO2019076919A1 (en)	2017-10-17	2019-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	COMBINED TREATMENT OF CYSTIC FIBROSIS
US11555189B2 (en)	2017-10-18	2023-01-17	Sarepta Therapeutics, Inc.	Antisense oligomer compounds
SG11202002940QA (en)	2017-11-01	2020-04-29	Alnylam Pharmaceuticals Inc	Complement component c3 irna compositions and methods of use thereof
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US20200385719A1 (en)	2017-11-16	2020-12-10	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
WO2019115416A2 (en)	2017-12-11	2019-06-20	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating fndc3b expression
WO2019115417A2 (en)	2017-12-12	2019-06-20	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating rb1 expression
US11725208B2 (en)	2017-12-14	2023-08-15	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
EP3728593A1 (de)	2017-12-18	2020-10-28	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen der high-mobility-group box-1 (hmgb1) und verfahren zur verwendung davon
US11459564B2 (en)	2017-12-21	2022-10-04	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
WO2019121838A1 (en)	2017-12-21	2019-06-27	F. Hoffmann-La Roche Ag	Companion diagnostic for htra1 rna antagonists
US11597926B2 (en)	2017-12-22	2023-03-07	Roche Innovation Center Copenhagen A/S	Thiophosphoramidites
CA3084170A1 (en)	2017-12-22	2019-06-27	Roche Innovation Center Copenhagen A/S	Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
WO2019122279A1 (en)	2017-12-22	2019-06-27	Roche Innovation Center Copenhagen A/S	Oligonucleotides comprising a phosphorodithioate internucleoside linkage
SG11202006101WA (en)	2017-12-29	2020-07-29	Scripps Research Inst	Unnatural base pair compositions and methods of use
US20210095274A1 (en)	2018-01-10	2021-04-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating pias4 expression
SG11202006528XA (en)	2018-01-12	2020-08-28	Bristol Myers Squibb Co	Antisense oligonucleotides targeting alpha-synuclein and uses thereof
SG11202006142PA (en)	2018-01-12	2020-07-29	Roche Innovation Ct Copenhagen As	Alpha-synuclein antisense oligonucleotides and uses thereof
CN120310791A (zh)	2018-01-12	2025-07-15	百时美施贵宝公司	靶向α-突触核蛋白的反义寡核苷酸及其用途
WO2019137974A1 (en)	2018-01-12	2019-07-18	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating gsk3b expression
AU2019206731A1 (en)	2018-01-15	2020-07-30	Ionis Pharmaceuticals, Inc.	Modulators of DNM2 expression
CN111615558A (zh)	2018-01-17	2020-09-01	罗氏创新中心哥本哈根有限公司	用于调节erc1表达的寡核苷酸
CN111655851A (zh)	2018-01-18	2020-09-11	哥本哈根罗氏创新中心	靶向srebp1的反义寡核苷酸
EP3740580A4 (de)	2018-01-19	2021-10-20	Duke University	Genom-engineering mit crispr-cas-systemen bei eukaryonten
WO2019145386A1 (en)	2018-01-26	2019-08-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating csnk1d expression
BR112020016170A2 (pt)	2018-02-09	2020-12-15	Genentech, Inc.	Oligonucleotídeos terapêutico e antissenso, conjugado, sal farmaceuticamente aceitável, composição farmacêutica, método in vitro ou in vivo para modular a expressão de tmem106b, método para tratar ou prevenir uma doença, uso do oligonucleotídeo e uso ou método
WO2019157531A1 (en)	2018-02-12	2019-08-15	Ionis Pharmaceuticals, Inc.	Modified compounds and uses thereof
MX2020008581A (es)	2018-02-21	2020-09-21	Bristol Myers Squibb Co	Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos.
CN112004547A (zh)	2018-02-26	2020-11-27	新索思股份有限公司	Il-15缀合物及其用途
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
US11732260B2 (en)	2018-03-02	2023-08-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-β precursor protein
MX2020009532A (es)	2018-03-13	2020-10-05	Janssen Pharmaceutica Nv	Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
WO2019183440A1 (en)	2018-03-22	2019-09-26	Ionis Pharmaceuticals, Inc.	Methods for modulating fmr1 expression
SG11202009680XA (en)	2018-04-05	2020-10-29	Hoffmann La Roche	Use of fubp1 inhibitors for treating hepatitis b virus infection
SG11202008660TA (en)	2018-04-11	2020-10-29	Ionis Pharmaceuticals Inc	Modulators of ezh2 expression
WO2019213016A1 (en)	2018-04-30	2019-11-07	The Children's Hospital Of Philadelphia	Methods of improving anemias by combining agents
CA3099280A1 (en)	2018-05-04	2019-11-07	Stoke Therapeutics, Inc.	Methods and compositions for treatment of cholesteryl ester storage disease
MX2020011570A (es)	2018-05-07	2020-11-24	Alnylam Pharmaceuticals Inc	Administracion extrahepatica.
CN112105745A (zh)	2018-05-07	2020-12-18	罗氏创新中心哥本哈根有限公司	用于寡核苷酸治疗剂的大规模平行发现方法
US20210371860A1 (en)	2018-05-08	2021-12-02	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating myh7 expression
EP4663758A3 (de)	2018-05-09	2026-04-29	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur reduzierung der atxn3-expression
CU20200082A7 (es)	2018-05-09	2021-06-08	Ionis Pharmaceuticals Inc	Compuestos y métodos para la reducción de la expresión de fxi
US12582702B2 (en)	2018-05-11	2026-03-24	University Of Massachusetts	Methods for improving leptin sensitivity for the treatment of obesity and diabetes
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
JP2021524450A (ja)	2018-05-18	2021-09-13	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	マイクロｒｎａ関連疾患の処置のための薬学的組成物
GB201808146D0 (en)	2018-05-18	2018-07-11	Proqr Therapeutics Ii Bv	Stereospecific Linkages in RNA Editing Oligonucleotides
WO2019224172A1 (en)	2018-05-25	2019-11-28	Roche Innovation Center Copenhagen A/S	Novel process for making allofuranose from glucofuranose
US10758629B2 (en)	2018-05-29	2020-09-01	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
JP7379387B2 (ja)	2018-06-05	2023-11-14	エフ．ホフマン－ラロシュアーゲー	Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
EP3806868A4 (de)	2018-06-13	2022-06-22	Sarepta Therapeutics, Inc.	Exon-skipping-oligomere für muskeldystrophie
CA3103429A1 (en)	2018-06-14	2019-12-19	Don W. Cleveland	Compounds and methods for increasing stmn2 expression
EP3810151B1 (de)	2018-06-20	2025-08-06	Yale University	Rig-i-agonisten und diese verwendende behandlungen
JP7595464B2 (ja)	2018-06-21	2024-12-06	エフ．ホフマン－ラロシュアーゲー	全ｌｎａオリゴヌクレオチドのハイブリダイズ
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
WO2020007702A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting bcl2l11
WO2020007700A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting spi1
WO2020007772A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting gbp-1
PE20210346A1 (es)	2018-07-03	2021-02-25	Hoffmann La Roche	Oligonucleotidos para modular la expresion de tau
WO2020007889A1 (en)	2018-07-05	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting stat1
WO2020007826A1 (en)	2018-07-05	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting mbtps1
WO2020011743A1 (en)	2018-07-09	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting mafb
WO2020011653A1 (en)	2018-07-09	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting kynu
WO2020011745A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting cers6
WO2020011869A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting tlr2
WO2020011744A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting cers5
CN112534055A (zh)	2018-07-13	2021-03-19	豪夫迈·罗氏有限公司	用于调节rtel1表达的寡核苷酸
US12496311B2 (en)	2018-07-17	2025-12-16	Aronora, Inc.	Methods for safely reducing thrombopoietin
AR115847A1 (es)	2018-07-25	2021-03-03	Ionis Pharmaceuticals Inc	Compuestos y métodos para reducir la expresión de la atxn2
TW202449155A (zh)	2018-07-27	2024-12-16	美商薩羅塔治療公司	用於肌肉萎縮症之外顯子跳躍寡聚物
BR112020025272A2 (pt)	2018-07-31	2021-03-09	Roche Innovation Center Copenhagen A/S	Oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção
EP4122943B1 (de)	2018-07-31	2024-05-29	Roche Innovation Center Copenhagen A/S	Oligonukleotide mit einer phosphordithioat-internukleosid-verknüpfung
JP7625512B2 (ja)	2018-08-13	2025-02-03	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
TW202020157A (zh)	2018-08-16	2020-06-01	美商艾爾妮蘭製藥公司	用於抑制lect2基因表現之組合物及方法
BR112021003224A2 (pt)	2018-08-20	2021-07-20	Rogcon, Inc.	oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a
WO2020038973A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting sptlc1
WO2020038971A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting vcan
WO2020038976A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting usp8
CN112585280A (zh)	2018-08-23	2021-03-30	罗氏创新中心哥本哈根有限公司	微小rna-134生物标志物
WO2020043750A1 (en)	2018-08-28	2020-03-05	Roche Innovation Center Copenhagen A/S	Neoantigen engineering using splice modulating compounds
CA3110661A1 (en)	2018-08-29	2020-03-05	University Of Massachusetts	Inhibition of protein kinases to treat friedreich ataxia
EP3620519A1 (de)	2018-09-04	2020-03-11	F. Hoffmann-La Roche AG	Verwendung von isolierten extrazellulären vesikeln aus milch zur oralen verabreichung von oligonukleotiden
US11273137B2 (en)	2018-09-04	2022-03-15	Board Of Trustees Of Michigan State University	Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
CA3111562A1 (en)	2018-09-07	2020-04-02	The General Hospital Corporation	Compositions and methods for immune checkpoint inhibition
EP3620520A1 (de)	2018-09-10	2020-03-11	Universidad del Pais Vasco	Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
US20210332367A1 (en)	2018-09-18	2021-10-28	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TW202542311A (zh)	2018-09-19	2025-11-01	美商Ionis製藥公司	Pnpla3表現之調節劑
WO2020069055A1 (en)	2018-09-28	2020-04-02	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
JP2022512877A (ja)	2018-11-01	2022-02-07	エフ．ホフマン－ラロシュアーゲー	Ｔｉａ１を標的とするアンチセンスオリゴヌクレオチド
SG11202102930YA (en)	2018-11-08	2021-04-29	Synthorx Inc	Interleukin 10 conjugates and uses thereof
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
CR20210311A (es)	2018-11-15	2021-07-22	Ionis Pharmaceuticals Inc	Moduladores de la expresión de irf5
US12281305B2 (en)	2018-11-21	2025-04-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing prion expression
WO2020104492A1 (en)	2018-11-22	2020-05-28	Roche Innovation Center Copenhagen A/S	Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides
WO2020109343A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Combination therapy for treatment of macular degeneration
WO2020109344A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Occular administration device for antisense oligonucleotides
WO2020117706A1 (en)	2018-12-03	2020-06-11	Triplet Therapeutics, Inc.	Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
IL318474A (en)	2018-12-13	2025-03-01	Sarepta Therapeutics Inc	Axon-skipping oligomer complexes for muscular dystrophy
CN112654714B (zh)	2018-12-17	2024-10-11	伊卢米纳剑桥有限公司	用于测序的引物寡核苷酸
RS67553B1 (sr)	2018-12-20	2026-01-30	Humabs Biomed Sa	Kombinovana hbv terapija
AU2019406186A1 (en)	2018-12-20	2021-07-15	Praxis Precision Medicines, Inc.	Compositions and methods for the treatment of KCNT1 related disorders
WO2020136125A2 (en)	2018-12-21	2020-07-02	Boehringer Ingelheim International Gmbh	Antisense oligonucleotides targeting card9
CR20210395A (es)	2018-12-21	2021-11-05	Ionis Pharmaceuticals Inc	Moduladores de la expresión de hsd17b13
MX2021008628A (es)	2019-01-16	2021-11-17	Genzyme Corp	Composiciones de arni para serpinc1 y metodos de uso de las mismas.
EP3914232A1 (de)	2019-01-25	2021-12-01	F. Hoffmann-La Roche AG	Lipidvesikel zur oralen wirkstoffverabreichung
BR112021013369A2 (pt)	2019-01-31	2021-09-21	Ionis Pharmaceuticals, Inc.	Moduladores de expressão de yap1
EP3923974A4 (de)	2019-02-06	2023-02-08	Synthorx, Inc.	Il-2-konjugate und verfahren zur verwendung davon
TW202102516A (zh)	2019-02-20	2021-01-16	丹麥商羅氏創新中心哥本哈根有限公司	膦醯基乙酸酯間隙子寡核苷酸
TW202045521A (zh)	2019-02-20	2020-12-16	丹麥商羅氏創新中心哥本哈根有限公司	新穎亞磷醯胺化物
JP7503072B2 (ja)	2019-02-26	2024-06-19	ロシュイノベーションセンターコペンハーゲンエーエス	オリゴヌクレオチドの製剤化方法
AU2020227824B2 (en)	2019-02-27	2025-07-10	Ionis Pharmaceuticals, Inc.	Modulators of MALAT1 expression
AU2020227825B2 (en)	2019-02-27	2026-03-26	Stoke Therapeutics, Inc.	Antisense oligomers for treatment of conditions and diseases
US12215382B2 (en)	2019-03-01	2025-02-04	The General Hospital Corporation	Liver protective MARC variants and uses thereof
CN113507942A (zh)	2019-03-05	2021-10-15	豪夫迈·罗氏有限公司	分子的细胞内靶向
CA3132199A1 (en)	2019-03-12	2020-09-17	President And Fellows Of Harvard College	Methods and compositions for treating cancer
US20240108747A1 (en)	2019-03-21	2024-04-04	Lonza Sales Ag	Extracellular vesicle conjugates and uses thereof
WO2020191177A1 (en)	2019-03-21	2020-09-24	Sudhir Agrawal	Antisense oligonucleotides for allele specificity
PT3947684T (pt)	2019-03-29	2025-05-19	Ionis Pharmaceuticals Inc	Compostos e métodos para modular ube3a‑ats
EP3947680A2 (de)	2019-04-03	2022-02-09	Bristol-Myers Squibb Company	Angptl2-antisense-oligonukleotide und verwendungen davon
EP3947677A1 (de)	2019-04-04	2022-02-09	F. Hoffmann-La Roche AG	Oligonukleotide zur modulierung der atxn2-expression
US11286485B2 (en)	2019-04-04	2022-03-29	Hoffmann-La Roche Inc.	Oligonucleotides for modulating ATXN2 expression
US12421268B2 (en)	2019-04-16	2025-09-23	Roche Innovation Center Copenhagen A/S	Process for preparing nucleotide P(V) monomers
WO2020214763A1 (en)	2019-04-18	2020-10-22	Sarepta Therapeutics, Inc.	Compositions for treating muscular dystrophy
CN113767108A (zh)	2019-04-30	2021-12-07	罗氏创新中心哥本哈根有限公司	制备铼螯合mag3寡核苷酸的新方法
AU2020268798A1 (en)	2019-05-03	2021-11-04	Dicerna Pharmaceuticals, Inc.	Double-stranded nucleic acid inhibitor molecules with shortened sense strands
PH12021552870A1 (en)	2019-05-13	2022-03-21	Vir Biotechnology Inc	Compositions and methods for treating hepatitis b virus (hbv) infection
AU2020279101B2 (en)	2019-05-17	2025-07-24	Alnylam Pharmaceuticals, Inc.	Oral delivery of oligonucleotides
HRP20250468T1 (hr)	2019-05-28	2025-07-18	Ionis Pharmaceuticals. Inc.	SPOJEVI I METODE ZA SMANJENJE POKAZATELJA FUS-a
CN113950529A (zh)	2019-06-06	2022-01-18	豪夫迈·罗氏有限公司	靶向atxn3的反义寡核苷酸
CN120665985A (zh)	2019-06-07	2025-09-19	豪夫迈·罗氏有限公司	杂交全lna寡核苷酸
US20220226269A1 (en)	2019-06-12	2022-07-21	President And Fellows Of Harvard College	Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
AU2020291535A1 (en)	2019-06-14	2022-01-20	The Scripps Research Institute	Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
EP3997225A1 (de)	2019-07-10	2022-05-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur behandlung von epilepsie
WO2021021673A1 (en)	2019-07-26	2021-02-04	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating gfap
EP4007812A1 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
EP4007811A2 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4013870A1 (de)	2019-08-13	2022-06-22	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
CA3147366A1 (en)	2019-08-14	2021-02-18	Adam T. BOUTIN	Extracellular vesicles with stat3-antisense oligonucleotides
KR20220070433A (ko)	2019-08-14	2022-05-31	코디악 바이오사이언시즈, 인크.	Stat6을 표적으로 하는 세포외 소포-aso 작제물
AU2020330133A1 (en)	2019-08-14	2022-03-17	Lonza Sales Ag	Extracellular vesicle-ASO constructs targeting CEBP/beta
US20220354963A1 (en)	2019-08-14	2022-11-10	Codiak Biosciences, Inc.	Extracellular vesicle linked to molecules and uses thereof
CA3147701A1 (en)	2019-08-14	2021-02-18	Codiak Biosciences, Inc.	Extracellular vesicles with antisense oligonucleotides targeting kras
CA3147365A1 (en)	2019-08-14	2021-02-18	Joanne LIM	Extracellular vesicle-nlrp3 antagonist
KR20220062517A (ko)	2019-08-15	2022-05-17	아이오니스 파마수티컬즈, 인코포레이티드	결합 변형된 올리고머 화합물 및 이의 용도
CN114555128A (zh)	2019-08-15	2022-05-27	新索思股份有限公司	采用il-2缀合物的免疫肿瘤学组合疗法
EP4017540A1 (de)	2019-08-23	2022-06-29	Synthorx, Inc.	Il-15-konjugate und verwendungen davon
BR112022003860A2 (pt)	2019-09-03	2022-08-16	Alnylam Pharmaceuticals Inc	Composições e métodos para inibir a expressão do gene lect2
US12234271B2 (en)	2019-09-10	2025-02-25	Synthorx, Inc.	Il-2 conjugates and methods of use to treat autoimmune diseases
WO2021062058A1 (en)	2019-09-25	2021-04-01	Codiak Biosciences, Inc.	Sting agonist comprising exosomes for treating neuroimmunological disorders
US12503699B2 (en)	2019-10-04	2025-12-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing UGT1a1 gene expression
WO2021074772A1 (en)	2019-10-14	2021-04-22	Astrazeneca Ab	Modulators of pnpla3 expression
WO2021074657A1 (en)	2019-10-17	2021-04-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination treatment for cystic fibrosis
EP4045652A1 (de)	2019-10-18	2022-08-24	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
WO2021081026A1 (en)	2019-10-22	2021-04-29	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof
US20230040920A1 (en)	2019-11-01	2023-02-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
EP4051795A1 (de)	2019-11-01	2022-09-07	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zu deren verwendung
WO2021091986A1 (en)	2019-11-04	2021-05-14	Synthorx, Inc.	Interleukin 10 conjugates and uses thereof
BR112022007795A2 (pt)	2019-11-06	2022-07-05	Alnylam Pharmaceuticals Inc	Administração extra-hepática
WO2021092145A1 (en)	2019-11-06	2021-05-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
BR112022009216A2 (pt)	2019-11-13	2022-08-02	Alnylam Pharmaceuticals Inc	Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
US20230016983A1 (en)	2019-11-19	2023-01-19	lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)	Antisense oligonucleotides and thier use for the treatment of cancer
US12565653B2 (en)	2019-11-22	2026-03-03	Alnylam Pharmaceuticals, Inc.	ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof
KR20220115995A (ko)	2019-12-13	2022-08-19	알닐람 파마슈티칼스 인코포레이티드	인간 염색체 ９ 개방 판독 프레임 72 (C9orf72) iRNA 제제 조성물 및 이의 사용 방법
WO2021126734A1 (en)	2019-12-16	2021-06-24	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
AU2020407267A1 (en)	2019-12-18	2022-06-16	F. Hoffmann-La Roche Ag	Methods of sequencing by synthesis using a consecutive labeling scheme
WO2021122735A1 (en)	2019-12-19	2021-06-24	F. Hoffmann-La Roche Ag	Use of sept9 inhibitors for treating hepatitis b virus infection
EP4058032A4 (de)	2019-12-19	2024-01-10	Entrada Therapeutics, Inc.	Zusammensetzungen zur verabreichung von antisense-verbindungen
EP4077669A1 (de)	2019-12-19	2022-10-26	F. Hoffmann-La Roche AG	Verwendung von sbds-inhibitoren zur behandlung von hepatitis-b-virus-infektionen
WO2021122921A1 (en)	2019-12-19	2021-06-24	F. Hoffmann-La Roche Ag	Use of cops3 inhibitors for treating hepatitis b virus infection
WO2021122869A1 (en)	2019-12-19	2021-06-24	F. Hoffmann-La Roche Ag	Use of scamp3 inhibitors for treating hepatitis b virus infection
JP2023506954A (ja)	2019-12-19	2023-02-20	エフ．ホフマン－ラロシュエージー．	Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
EP4077672A1 (de)	2019-12-20	2022-10-26	F. Hoffmann-La Roche AG	Verbesserte oligonukleotide zur hemmung der scn9a-expression
MX2022007908A (es)	2019-12-24	2022-07-21	Hoffmann La Roche	Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
EP4081217A1 (de)	2019-12-24	2022-11-02	F. Hoffmann-La Roche AG	Pharmazeutische kombination von antivirusmitteln, die hbv und/oder einen immunmodulator zur behandlung von hbv steuern
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
WO2021158810A1 (en)	2020-02-05	2021-08-12	Bristol-Myers Squibb Company	Oligonucleotides for splice modulation of camk2d
IL295445A (en)	2020-02-10	2022-10-01	Alnylam Pharmaceuticals Inc	Preparations and methods for silencing vegf-a expression
TWI883391B (zh)	2020-02-18	2025-05-11	美商基利科學股份有限公司	抗病毒化合物
KR20250133471A (ko)	2020-02-18	2025-09-05	길리애드 사이언시즈, 인코포레이티드	항바이러스 화합물
JP7735288B2 (ja)	2020-02-18	2025-09-08	アルナイラムファーマシューティカルズ，インコーポレイテッド	アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法
TWI775313B (zh)	2020-02-18	2022-08-21	美商基利科學股份有限公司	抗病毒化合物
CN120505310A (zh)	2020-02-28	2025-08-19	Ionis制药公司	用于调节smn2的化合物和方法
EP4110916A1 (de)	2020-02-28	2023-01-04	F. Hoffmann-La Roche AG	Oligonukleotide zum modulieren von cd73-exon-7-spleissen
KR20230004456A (ko)	2020-03-04	2023-01-06	리제너론 파아마슈티컬스, 인크.	면역 요법에 대한 종양 세포의 감작화를 위한 방법 및 조성물
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
BR112022017822A2 (pt)	2020-03-06	2022-11-08	Alnylam Pharmaceuticals Inc	Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
CN115461460A (zh)	2020-03-06	2022-12-09	阿尔尼拉姆医药品有限公司	用于抑制转甲状腺素蛋白(ttr)的表达的组合物和方法
WO2021184021A1 (en)	2020-03-13	2021-09-16	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting pmp22
WO2021184020A1 (en)	2020-03-13	2021-09-16	Codiak Biosciences, Inc.	Methods of treating neuroinflammation
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
TW202204615A (zh)	2020-03-26	2022-02-01	美商阿尼拉製藥公司	冠狀病毒ｉＲＮＡ組成物及其使用方法
US20230190785A1 (en)	2020-03-30	2023-06-22	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
US20240092821A1 (en)	2020-03-31	2024-03-21	Janssen Biopharma, Inc.	Synthesis of oligonucleotides and related compounds
US12534731B2 (en)	2020-04-01	2026-01-27	Alnylam Pharmaceuticals, Inc.	Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
KR20230008729A (ko)	2020-04-06	2023-01-16	알닐람 파마슈티칼스 인코포레이티드	Myoc 발현을 사일런싱하기 위한 조성물 및 방법
EP4133076A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
EP4133077A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
JP2023521094A (ja)	2020-04-07	2023-05-23	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｓｃｎ９ａ発現をサイレンシングするための組成物および方法
CN115916262A (zh)	2020-04-21	2023-04-04	旗舰创业股份有限公司	双官能分子及其使用方法
IL297702A (en)	2020-04-27	2022-12-01	Alnylam Pharmaceuticals Inc	Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
JP2023523790A (ja)	2020-04-30	2023-06-07	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法
TWI901676B (zh)	2020-05-01	2025-10-21	美商Ionis製藥公司	調節ａｔｘｎ１之化合物及方法
CN115867657A (zh)	2020-05-11	2023-03-28	斯托克制药公司	用于治疗疾患和疾病的opa1反义寡聚物
EP4149486A1 (de)	2020-05-11	2023-03-22	Genentech, Inc.	Komplementkomponenten-c1s-inhibitoren zur behandlung einer neurologischen erkrankung sowie zugehörige zusammensetzungen, systeme und verfahren zur verwendung davon
WO2021231210A1 (en)	2020-05-11	2021-11-18	Genentech, Inc.	Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
JP2023525770A (ja)	2020-05-11	2023-06-19	ジェネンテック，インコーポレイテッド	神経学的疾患を処置するための補体ｃ４阻害剤および関連する組成物、ならびにそれを使用するシステムおよび方法
WO2021229036A1 (en)	2020-05-13	2021-11-18	F. Hoffmann-La Roche Ag	Oligonucleotide agonists targeting progranulin
EP4150087A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
EP4150090A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231698A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231691A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
WO2021231675A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231685A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
US20230183707A1 (en)	2020-05-21	2023-06-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
CN115884777A (zh)	2020-05-22	2023-03-31	豪夫迈·罗氏有限公司	用于card9的剪接调节的寡核苷酸
EP4157264A4 (de)	2020-05-27	2024-06-19	The Regents of the University of California	Zusammensetzungen und verfahren zur transdifferenzierung von zellen
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
US20230212572A1 (en)	2020-06-09	2023-07-06	Roche Innovation Center Copenhagen A/S	Guanosine Analogues for Use in Therapeutics Polynucleotides
EP4162050A1 (de)	2020-06-09	2023-04-12	Alnylam Pharmaceuticals, Inc.	Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
WO2021252649A2 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
WO2021257782A1 (en)	2020-06-18	2021-12-23	Alnylam Pharmaceuticals, Inc.	XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
PH12022553569A1 (en)	2020-06-24	2023-04-12	Humabs Biomed Sa	Engineered hepatitis b virus neutralizing antibodies and uses thereof
IL299074A (en)	2020-06-25	2023-02-01	Synthorx Inc	Immuno-oncology therapeutic combination with IL-2 and anti-AGFR antibody conjugates
AR122731A1 (es)	2020-06-26	2022-10-05	Hoffmann La Roche	Oligonucleótidos mejorados para modular la expresión de fubp1
EP4172338A4 (de)	2020-06-29	2025-06-11	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulierung von plp1
WO2022011214A1 (en)	2020-07-10	2022-01-13	Alnylam Pharmaceuticals, Inc.	Circular sirnas
KR20230050336A (ko)	2020-07-10	2023-04-14	인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸)	뇌전증을 치료하기 위한 방법과 조성물
JP2023534557A (ja)	2020-07-23	2023-08-09	エフ．ホフマン－ラロシュアーゲー	Ｒｎａ結合タンパク質部位を標的とするオリゴヌクレオチド
WO2022018155A1 (en)	2020-07-23	2022-01-27	F. Hoffmann-La Roche Ag	Lna oligonucleotides for splice modulation of stmn2
CA3189922A1 (en)	2020-07-28	2022-02-03	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing app expression
IL300258A (en)	2020-08-07	2023-03-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating SCN2A
CN116157522A (zh)	2020-08-21	2023-05-23	豪夫迈·罗氏有限公司	A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
WO2022056454A2 (en)	2020-09-14	2022-03-17	President And Fellows Of Harvard College	Methods and compositions for treating hpv-positive cancers
AU2021344422A1 (en)	2020-09-16	2023-05-04	Gordon J. Freeman	Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
TW202227102A (zh)	2020-09-22	2022-07-16	瑞典商阿斯特捷利康公司	治療脂肪肝病之方法
WO2022066847A1 (en)	2020-09-24	2022-03-31	Alnylam Pharmaceuticals, Inc.	Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
EP4225917A1 (de)	2020-10-05	2023-08-16	Alnylam Pharmaceuticals, Inc.	G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
US20230364127A1 (en)	2020-10-06	2023-11-16	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting stat6
JP2023546010A (ja)	2020-10-09	2023-11-01	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートを用いた免疫腫瘍療法
IL301611A (en)	2020-10-09	2023-05-01	Synthorx Inc	Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
CA3198823A1 (en)	2020-10-21	2022-04-28	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
CN116761885A (zh)	2020-10-23	2023-09-15	斯克利普斯研究所	包含非天然核苷酸的多核苷酸的逆转录
EP4232582A1 (de)	2020-10-23	2023-08-30	Alnylam Pharmaceuticals, Inc.	Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230107625A (ko)	2020-11-13	2023-07-17	알닐람 파마슈티칼스 인코포레이티드	응고 인자 V(F5) iRNA 조성물 및 이의 사용 방법
LT4136092T (lt)	2020-11-18	2024-09-25	Ionis Pharmaceuticals, Inc.	Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui
EP4247949A1 (de)	2020-11-23	2023-09-27	Alpha Anomeric SAS	Nukleinsäureduplexe
TW202237150A (zh)	2020-12-01	2022-10-01	美商艾拉倫製藥股份有限公司	用於抑制ｈａｏ１（羥基酸氧化酶１（乙醇酸氧化酶））基因表現的方法及組成物
AR124229A1 (es)	2020-12-03	2023-03-01	Hoffmann La Roche	Oligonucleótidos antisentido que actúan sobre atxn3
US20230060373A1 (en)	2020-12-03	2023-03-02	Hoffmann-La Roche Inc.	Antisense Oligonucleotides Targeting ATXN3
WO2022122613A1 (en)	2020-12-08	2022-06-16	F. Hoffmann-La Roche Ag	Novel synthesis of phosphorodithioate oligonucleotides
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
GB2603454A (en)	2020-12-09	2022-08-10	Ucl Business Ltd	Novel therapeutics for the treatment of neurodegenerative disorders
CR20230308A (es)	2020-12-11	2023-09-08	Civi Biopharma Inc	Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
AR124378A1 (es)	2020-12-18	2023-03-22	Hoffmann La Roche	Oligonucleótidos antisentido dirigida a progranulina
WO2022133278A2 (en)	2020-12-18	2022-06-23	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating factor xii
WO2022136140A1 (en)	2020-12-22	2022-06-30	F. Hoffmann-La Roche Ag	Oligonucleotides targeting xbp1
EP4271696A2 (de)	2020-12-31	2023-11-08	Alnylam Pharmaceuticals, Inc.	Oligonukleotid-prodrugs auf basis von mit cyclischem disulfid modifiziertem phosphat
EP4271695A2 (de)	2020-12-31	2023-11-08	Alnylam Pharmaceuticals, Inc.	Auf 2'-modifiziertem nukleosid basierende oligonukleotid-prodrugs
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202246500A (zh)	2021-02-02	2022-12-01	瑞士商赫孚孟拉羅股份公司	用於抑制ｒｔｅｌ１表現之增強型寡核苷酸
WO2022174102A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
TW202245843A (zh)	2021-02-12	2022-12-01	美商欣爍克斯公司	Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
EP4291654A2 (de)	2021-02-12	2023-12-20	Alnylam Pharmaceuticals, Inc.	Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen
EP4294456A1 (de)	2021-02-17	2023-12-27	Lonza Sales AG	Extrazelluläre vesikel, die über einen optimierten linker mit einem biologisch aktiven molekül verbunden sind und eine verankerungseinheit
CA3207944A1 (en)	2021-02-17	2022-08-25	Ajay Verma	Extracellular vesicle-nlrp3 antagonist
EP4298220A1 (de)	2021-02-25	2024-01-03	Alnylam Pharmaceuticals, Inc.	Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
AU2022226098A1 (en)	2021-02-26	2023-08-24	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2024508896A (ja)	2021-03-04	2024-02-28	アルナイラムファーマシューティカルズ，インコーポレイテッド	アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物およびその使用方法
WO2022192519A1 (en)	2021-03-12	2022-09-15	Alnylam Pharmaceuticals, Inc.	Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
EP4314296A2 (de)	2021-03-29	2024-02-07	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
EP4314016A1 (de)	2021-03-31	2024-02-07	Entrada Therapeutics, Inc.	Zyklische zellen penetrierende peptide
KR20230166101A (ko)	2021-04-01	2023-12-06	론자 세일즈 아게	세포외 소포 조성물
EP4314293A1 (de)	2021-04-01	2024-02-07	Alnylam Pharmaceuticals, Inc.	Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
CA3216162A1 (en)	2021-04-16	2022-10-20	Gilead Sciences, Inc.	Methods of preparing carbanucleosides using amides
EP4330392A1 (de)	2021-04-26	2024-03-06	Alnylam Pharmaceuticals, Inc.	Transmembranprotease, serin 6 (tmprss6)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022232343A1 (en)	2021-04-29	2022-11-03	Alnylam Pharmaceuticals, Inc.	Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
WO2022240760A2 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
EP4337263A1 (de)	2021-05-10	2024-03-20	Entrada Therapeutics, Inc.	Zusammensetzungen und verfahren zur modulation der interferon-regulatorischen faktor-5 (irf-5)-aktivität
AU2022271873A1 (en)	2021-05-10	2024-01-04	Entrada Therapeutics, Inc.	Compositions and methods for intracellular therapeutics
EP4341401A1 (de)	2021-05-18	2024-03-27	Alnylam Pharmaceuticals, Inc.	Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4341405A1 (de)	2021-05-20	2024-03-27	Korro Bio, Inc.	Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
EP4347823A1 (de)	2021-06-02	2024-04-10	Alnylam Pharmaceuticals, Inc.	Patin-ähnliche phospholipasedomäne mit 3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4346904A1 (de)	2021-06-03	2024-04-10	Synthorx, Inc.	Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und cetuximab
EP4347822A2 (de)	2021-06-04	2024-04-10	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen mit offenem leserahmen 72 (c9orf72) auf menschlichem chromosom 9 und verfahren zur verwendung davon
AR126070A1 (es)	2021-06-08	2023-09-06	Alnylam Pharmaceuticals Inc	Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
CA3222546A1 (en)	2021-06-08	2022-12-15	F. Hoffmann-La Roche Ag	Oligonucleotide progranulin agonists
AU2022293556A1 (en)	2021-06-18	2024-01-18	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing ifnar1 expression
US12104159B2 (en)	2021-06-22	2024-10-01	AcuraStem Incorporated	PIKFYVE antisense oligonucleotides
AU2022298774A1 (en)	2021-06-23	2023-12-14	Entrada Therapeutics, Inc.	Antisense compounds and methods for targeting cug repeats
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
EP4363574A1 (de)	2021-06-29	2024-05-08	Korro Bio, Inc.	Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
AU2022303164A1 (en)	2021-06-30	2024-01-18	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2023283403A2 (en)	2021-07-09	2023-01-12	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
WO2023003805A1 (en)	2021-07-19	2023-01-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
MX2024000981A (es)	2021-07-21	2024-02-12	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) de gen diana asociado con trastorno metabolico y sus metodos de uso.
WO2023004049A1 (en)	2021-07-21	2023-01-26	AcuraStem, Inc.	Unc13a antisense oligonucleotides
AU2022316139A1 (en)	2021-07-23	2024-01-18	Alnylam Pharmaceuticals, Inc.	Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2023009687A1 (en)	2021-07-29	2023-02-02	Alnylam Pharmaceuticals, Inc.	3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
CA3227852A1 (en)	2021-08-03	2023-02-09	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof
EP4381071A1 (de)	2021-08-04	2024-06-12	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen und verfahren zur ausschaltung von angiotensinogen (att)
CN118076737A (zh)	2021-08-13	2024-05-24	阿尔尼拉姆医药品有限公司	因子XII（F12）iRNA组合物及其使用方法
WO2023021046A1 (en)	2021-08-16	2023-02-23	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
AU2022328698B2 (en)	2021-08-18	2025-02-20	Gilead Sciences, Inc.	Phospholipid compounds and methods of making and using the same
JP2024538859A (ja)	2021-08-31	2024-10-24	アルナイラムファーマシューティカルズ，インコーポレイテッド	細胞死誘導ＤＦＦＡ様エフェクターＢ（ＣＩＤＥＢ）ｉＲＮＡ組成物およびその使用方法
WO2023034870A2 (en)	2021-09-01	2023-03-09	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing dmpk expression
MX2024002640A (es)	2021-09-01	2024-07-19	Entrada Therapeutics Inc	Compuestos y metodos para salto de exon 44 en la distrofia muscular de duchenne.
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
AU2022345881A1 (en)	2021-09-20	2024-03-21	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
TW202328449A (zh)	2021-09-24	2023-07-16	美商艾拉倫製藥公司	微管相關蛋白ＴＡＵ（ＭＡＰＴ）ｉＲＮＡ試劑組合物及其使用方法
JP2024536132A (ja)	2021-09-29	2024-10-04	エフ．ホフマン－ラロシュアーゲー	Ｒｎａ編集方法
WO2023055774A1 (en)	2021-09-30	2023-04-06	Sarepta Therapeutics, Inc.	Antisense oligonucleotides having one or more abasic units
US12042509B2 (en)	2021-10-01	2024-07-23	Adarx Pharmaceuticals, Inc.	Prekallikrein-modulating compositions and methods of use thereof
CN118369427A (zh)	2021-10-15	2024-07-19	阿尔尼拉姆医药品有限公司	肝外递送irna组合物及其使用方法
WO2023069603A1 (en)	2021-10-22	2023-04-27	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
EP4419680A1 (de)	2021-10-22	2024-08-28	Sarepta Therapeutics, Inc.	Morpholinooligomere zur behandlung von erkrankungen im zusammenhang mit peripherem myelinprotein 22
EP4423272A2 (de)	2021-10-29	2024-09-04	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
CN118302525A (zh)	2021-10-29	2024-07-05	阿尔尼拉姆医药品有限公司	补体因子B（CFB）iRNA组合物及其使用方法
CN118318042A (zh)	2021-11-03	2024-07-09	豪夫迈·罗氏有限公司	用于调节载脂蛋白e4表达的寡核苷酸
US20250019702A1 (en)	2021-11-10	2025-01-16	University Of Rochester	Gata4-targeted therapeutics for treatment of cardiac hypertrophy
KR20240101580A9 (ko)	2021-11-11	2025-12-10	에프. 호프만-라 로슈 아게	Hbv 치료를 위한 약학 조합물
EP4433592A1 (de)	2021-11-18	2024-09-25	Circularis Biotechnologies, Inc.	Zusammensetzungen und verfahren zur herstellung von zirkulären nukleinsäuremolekülen
WO2023092102A1 (en)	2021-11-19	2023-05-25	Sanegene Bio Usa Inc.	Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof
EP4437106A2 (de)	2021-11-24	2024-10-02	Prime Medicine, Inc.	Verfahren und zusammensetzungen zur verhinderung der reparatur von fehlpaarungen
EP4441224A4 (de)	2021-12-03	2026-03-11	Quralis Corp	Gapmer-antisense-oligonukleotide mit modifizierter rückgratchemie
WO2023104693A1 (en)	2021-12-07	2023-06-15	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting actl6b
GB202117758D0 (en)	2021-12-09	2022-01-26	Ucl Business Ltd	Therapeutics for the treatment of neurodegenerative disorders
WO2023111210A1 (en)	2021-12-17	2023-06-22	F. Hoffmann-La Roche Ag	Combination of oligonucleotides for modulating rtel1 and fubp1
JP2024546887A (ja)	2021-12-17	2024-12-26	ジェネンテック，インコーポレイテッド	オリゴヌクレオチドｇｂａアゴニスト
WO2023117738A1 (en)	2021-12-20	2023-06-29	F. Hoffmann-La Roche Ag	Threose nucleic acid antisense oligonucleotides and methods thereof
EP4452327A1 (de)	2021-12-20	2024-10-30	Synthorx, Inc.	Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und pembrolizumab
KR20240126870A (ko)	2021-12-22	2024-08-21	캠프4 테라퓨틱스 코포레이션	조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
TW202340468A (zh)	2022-01-10	2023-10-16	中國大陸商杭州浩博醫藥有限公司	B型肝炎病毒(hbv)表現之調節
WO2023141507A1 (en)	2022-01-20	2023-07-27	Genentech, Inc.	Antisense oligonucleotides for modulating tmem106b expression
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
US20250230412A1 (en)	2022-02-01	2025-07-17	President And Fellows Of Harvard College	Methods and compositions for treating cancer
WO2023152369A1 (en)	2022-02-14	2023-08-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
AR128558A1 (es)	2022-02-21	2024-05-22	Hoffmann La Roche	Oligonucleótido antisentido
WO2023212625A1 (en)	2022-04-28	2023-11-02	AcuraStem Incorporated	Syf2 antisense oligonucleotides
US20240002857A1 (en)	2022-05-09	2024-01-04	Sanegene Bio Usa Inc.	Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
CN119173632A (zh)	2022-05-10	2024-12-20	豪夫迈·罗氏有限公司	靶向cfp-elk1基因间区域的反义寡核苷酸
EP4522742A2 (de)	2022-05-13	2025-03-19	Alnylam Pharmaceuticals, Inc.	Einzelsträngige schleifenoligonukleotide
WO2023222858A1 (en)	2022-05-18	2023-11-23	F. Hoffmann-La Roche Ag	Improved oligonucleotides targeting rna binding protein sites
IL317425A (en)	2022-06-10	2025-02-01	Camp4 Therapeutics Corp	Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory RNAs
CN119365600A (zh)	2022-06-17	2025-01-24	豪夫迈·罗氏有限公司	靶向颗粒蛋白前体的反义寡核苷酸
JP2025522880A (ja)	2022-06-30	2025-07-17	アルナイラムファーマシューティカルズ，インコーポレイテッド	環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
WO2024017990A1 (en)	2022-07-21	2024-01-25	Institut National de la Santé et de la Recherche Médicale	Methods and compositions for treating chronic pain disorders
CN120659627A (zh)	2022-07-29	2025-09-16	瑞泽恩制药公司	用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
KR20250046303A (ko)	2022-08-05	2025-04-02	사네진 바이오 유에스에이 인크.	안지오텐시노겐 (agt)을 표적화하는 이중 가닥 rna 및 그의 사용 방법
WO2024040041A1 (en)	2022-08-15	2024-02-22	Dicerna Pharmaceuticals, Inc.	Regulation of activity of rnai molecules
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
CA3265664A1 (en)	2022-08-25	2024-02-29	Life Edit Therapeutics, Inc.	CHEMICAL MODIFICATION OF GUIDE RNA WITH A LOCKED NUCLEIC ACID FOR RNA-GUIDED NUCLEASE-MEDIATED GENE EDITING
WO2024050261A1 (en)	2022-08-29	2024-03-07	University Of Rochester	Antisense oligonucleotide-based anti-fibrotic therapeutics
EP4332221A1 (de)	2022-08-29	2024-03-06	Roche Innovation Center Copenhagen A/S	Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
KR20250059413A (ko)	2022-09-06	2025-05-02	에프. 호프만-라 로슈 아게	눈에 투여하기 위한 이중 가닥 rna 분자
EP4569113A1 (de)	2022-09-15	2025-06-18	Regeneron Pharmaceuticals, Inc.	17b-hydroxysteroiddehydrogenase-typ-13 (hsd17b13)-irna-zusammensetzungen und verfahren zu ihrer verwendung
JP2025533454A (ja)	2022-09-21	2025-10-07	サレプタセラピューティクス，インコーポレイテッド	Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
JP2025532127A (ja)	2022-09-23	2025-09-29	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｍｅｃｐ２発現を低減する化合物及び方法
WO2024073732A1 (en)	2022-09-30	2024-04-04	Alnylam Pharmaceuticals, Inc.	Modified double-stranded rna agents
KR20250088573A (ko)	2022-10-14	2025-06-17	사네진 바이오 유에스에이 인크.	C3을 표적화하는 소형 간섭 rna 및 그의 용도
WO2024098061A2 (en)	2022-11-04	2024-05-10	Genkardia Inc.	Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
EP4612184A1 (de)	2022-11-04	2025-09-10	Regeneron Pharmaceuticals, Inc.	An die calcium-spannungsabhängige kanalhilfsuntereinheit gamma 1 (cacng1) bindende proteine und cacng1-vermittelte abgabe an skelettmuskeln
KR20250116795A (ko)	2022-11-14	2025-08-01	리제너론 파마슈티칼스 인코포레이티드	별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
EP4627084A1 (de)	2022-12-01	2025-10-08	Camp4 Therapeutics Corporation	Modulation der syngap1-gentranskription unter verwendung von gegen regulatorische rnas gerichteten antisense-oligonukleotiden
WO2024126654A1 (en)	2022-12-14	2024-06-20	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting actl6b
WO2024137590A2 (en)	2022-12-19	2024-06-27	Sanegene Bio Usa Inc.	Small interfering rna targeting cfb and uses thereof
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
EP4646478A1 (de)	2023-01-06	2025-11-12	Institut National de la Santé et de la Recherche Médicale	Intravenöse verabreichung von antisense-oligonukleotiden zur behandlung von schmerzen
EP4652276A2 (de)	2023-01-20	2025-11-26	AcuraStem Incorporated	Unc13a-antisense-oligonukleotide
WO2024160756A1 (en)	2023-01-30	2024-08-08	Vib Vzw	Suppressors of tauopathies
AU2024215901A1 (en)	2023-01-31	2025-07-24	AcuraStem Incorporated	Syf2 antisense oligonucleotides
WO2024167945A1 (en)	2023-02-06	2024-08-15	AcuraStem Incorporated	Pikfyve antisense oligonucleotides
TW202449152A (zh)	2023-02-09	2024-12-16	美商艾拉倫製藥股份有限公司	Ｒｅｖｅｒｓｉｒ分子及其使用方法
EP4669750A2 (de)	2023-02-21	2025-12-31	Vib Vzw	Inhibitoren der synaptogyrin-3-expression
WO2024175588A1 (en)	2023-02-21	2024-08-29	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
US20240309383A1 (en)	2023-02-24	2024-09-19	Suzhou Sanegene Bio Inc.	Small interfering rna targeting hbv and uses thereof
WO2024186673A2 (en)	2023-03-03	2024-09-12	Sanegene Bio Usa Inc.	Small interfering rna targeting apoc3 and uses thereof
CN121263208A (zh)	2023-03-20	2026-01-02	新索思股份有限公司	使用il-2 peg缀合物的癌症疗法
KR20260009305A (ko)	2023-04-12	2026-01-19	알닐람 파마슈티칼스 인코포레이티드	이중 가닥 rna 제제의 간외 전달
TW202448484A (zh)	2023-04-20	2024-12-16	美商雅迪克斯製藥公司	Ｍａｐｔ調節組合物及其使用方法
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
TW202442246A (zh)	2023-04-27	2024-11-01	美商薩羅塔治療公司	用於治療慢性腎病之反義寡聚物
CN121079412A (zh)	2023-04-28	2025-12-05	比姆医疗股份有限公司	经修饰的指导rna
EP4705457A2 (de)	2023-05-04	2026-03-11	F. Hoffmann-La Roche AG	Oligonukleotide zur hochregulierung der glucocerebrosidase-expression
WO2024233864A2 (en)	2023-05-10	2024-11-14	Dicerna Pharmaceuticals, Inc.	Galnac-conjugated rnai oligonucleotides
WO2024238396A1 (en)	2023-05-12	2024-11-21	Adarx Pharmaceuticals, Inc.	Nmda ligand conjugated compounds and uses thereof
EP4709855A2 (de)	2023-05-12	2026-03-18	Alnylam Pharmaceuticals, Inc.	Einzelsträngige schleifenoligonukleotide
CN121335980A (zh)	2023-05-26	2026-01-13	阿达尔克斯制药有限公司	Sod1调节组合物及其使用方法
TW202516004A (zh)	2023-06-16	2025-04-16	瑞士商赫孚孟拉羅股份公司	調節ｊａｋ１表現之雙股寡核苷酸
EP4731763A1 (de)	2023-06-20	2026-04-29	Adarx Pharmaceuticals, Inc.	Lrrk2-modulierende zusammensetzungen und verfahren zur verwendung davon
WO2024263915A2 (en)	2023-06-21	2024-12-26	Sanegene Bio Usa Inc.	Double stranded rna targeting proprotein convertase subtilisin kexin 9 (pcsk9) and methods of use thereof
WO2025008406A1 (en)	2023-07-04	2025-01-09	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotides and their use for the treatment of cancer
WO2025015335A1 (en)	2023-07-13	2025-01-16	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
AU2024299328A1 (en)	2023-07-21	2026-01-22	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
WO2025024493A1 (en)	2023-07-25	2025-01-30	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
KR20260044217A (ko)	2023-07-25	2026-04-01	플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨	Cas 엔도뉴클레아제 및 관련 방법
KR20260049597A (ko)	2023-08-04	2026-04-14	알닐람 파마슈티칼스 인코포레이티드	Ctnnb1-관련 질환을 치료하기 위한 방법 및 조성물
WO2025038750A2 (en)	2023-08-14	2025-02-20	President And Fellows Of Harvard College	Methods and compositions for treating cancer
WO2025054459A1 (en)	2023-09-08	2025-03-13	Dicerna Pharmaceuticals, Inc.	Rnai oligonucleotide conjugates
WO2025064660A2 (en)	2023-09-21	2025-03-27	Alnylam Pharmaceuticals, Inc.	Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
WO2025072331A1 (en)	2023-09-26	2025-04-03	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
WO2025080939A1 (en)	2023-10-13	2025-04-17	Ultragenyx Pharmaceutical, Inc.	Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations
WO2025085810A2 (en)	2023-10-18	2025-04-24	Sarepta Therapeutics, Inc.	Antisense oligomers for treatment of centronuclear myopathies
WO2025096809A1 (en)	2023-10-31	2025-05-08	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025117877A2 (en)	2023-12-01	2025-06-05	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025128853A2 (en)	2023-12-13	2025-06-19	Ultragenyx Pharmaceutical Inc.	Compositions and methods for treating conditions associated with ube3a overexpression
WO2025132962A2 (en)	2023-12-21	2025-06-26	F. Hoffmann-La Roche Ag	Antisense oligonucleotide
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2025178854A2 (en)	2024-02-19	2025-08-28	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
WO2025199231A2 (en)	2024-03-20	2025-09-25	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en)	2024-03-25	2025-10-02	Synthorx, Inc.	Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
GB202404290D0 (en)	2024-03-26	2024-05-08	Senisca Ltd	Novel oligoncleotides
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025228441A2 (en)	2024-04-30	2025-11-06	Sanegene Bio Usa Inc.	Small interfering rna targeting inhbe and uses thereof
WO2025237990A1 (en)	2024-05-14	2025-11-20	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025252669A1 (en)	2024-06-03	2025-12-11	Evotec International Gmbh	Modified oligonucleotides for reducing atxn3 expression
WO2025255388A1 (en)	2024-06-05	2025-12-11	Camp4 Therapeutics Corporation	Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026017140A2 (en)	2024-07-18	2026-01-22	Sanegene Bio Usa Inc.	Small interfering rna targeting fxi and uses thereof
WO2026041067A2 (en)	2024-08-20	2026-02-26	Sanegene Bio Usa Inc.	Small interfering rna targeting myostatin (mstn) and uses thereof
WO2026041784A1 (en)	2024-08-23	2026-02-26	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
WO2026050243A1 (en)	2024-08-26	2026-03-05	Korro Bio, Inc.	Galnac conjugated oligonucleotides for rna editing
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
EP4711455A1 (de)	2024-09-11	2026-03-18	Aarhus Universitet	Oligonukleotid aus kleiner künstlicher rna (smartrna) zur modulation der proteinexpression
WO2026057749A1 (en)	2024-09-11	2026-03-19	Sixfold Bioscience Ltd.	Method and product
WO2026061986A1 (en)	2024-09-17	2026-03-26	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
WO2026062247A1 (en)	2024-09-20	2026-03-26	Astrazeneca Ab	Liquid-phase oligonucleotide synthesis using 2-(2-nitrophenyl)propyloxycarbonyl (nppoc) as a protecting group
WO2026080323A1 (en)	2024-10-09	2026-04-16	Quralis Corporation	Treatment of neurological diseases using modulators of unc13a gene transcripts

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4837312A (en)	1985-01-25	1989-06-06	California Institute Of Technology	Chelator-functionalized nucleosides and nucleotides and methods for making same
EP0538194B1 (de)	1991-10-17	1997-06-04	Novartis AG	Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
DE69233046T2 (de)	1991-10-24	2004-03-04	Isis Pharmaceuticals, Inc., Carlsfeld	Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5559101A (en) *	1994-10-24	1996-09-24	Genencor International, Inc.	L-ribofuranosyl nucleosides
ATE238328T1 (de)	1996-10-16	2003-05-15	Ribapharm Inc	Monozyklische l-nukleoside, analoga und ihre anwendungen
ES2192672T3 (es)	1996-11-18	2003-10-16	Takeshi Imanishi	Nuevos analogos de nucleotidos.
JP3756313B2 (ja) *	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) *	1997-09-12	2009-03-11	エクシコンエ／エス	オリゴヌクレオチド類似体
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
US6436640B1 (en) *	1999-03-18	2002-08-20	Exiqon A/S	Use of LNA in mass spectrometry
US6525191B1 (en)	1999-05-11	2003-02-25	Kanda S. Ramasamy	Conformationally constrained L-nucleosides

2000
- 2000-05-04 US US09/565,699 patent/US7053207B2/en not_active Expired - Lifetime
- 2000-05-04 NZ NZ514348A patent/NZ514348A/en not_active IP Right Cessation
- 2000-05-04 DK DK00925080T patent/DK1178999T3/da active
- 2000-05-04 EP EP00925080A patent/EP1178999B1/de not_active Revoked
- 2000-05-04 AU AU43918/00A patent/AU776362B2/en not_active Expired
- 2000-05-04 HK HK02107777.2A patent/HK1048322A1/zh unknown
- 2000-05-04 JP JP2000615633A patent/JP2002543214A/ja active Pending
- 2000-05-04 CA CA002372085A patent/CA2372085C/en not_active Expired - Lifetime
- 2000-05-04 DE DE60033927T patent/DE60033927T2/de not_active Revoked
- 2000-05-04 PT PT00925080T patent/PT1178999E/pt unknown
- 2000-05-04 CN CN00807070A patent/CN1349541A/zh active Pending
- 2000-05-04 ES ES00925080T patent/ES2283298T3/es not_active Expired - Lifetime
- 2000-05-04 KR KR1020017012177A patent/KR100782896B1/ko not_active Expired - Lifetime
- 2000-05-04 IL IL14549700A patent/IL145497A0/xx unknown
- 2000-05-04 AT AT00925080T patent/ATE356824T1/de not_active IP Right Cessation
- 2000-05-04 WO PCT/DK2000/000225 patent/WO2000066604A2/en not_active Ceased
- 2000-05-04 CN CN2011100346082A patent/CN102180924A/zh active Pending

Also Published As

Publication number	Publication date
DE60033927D1 (de)	2007-04-26
IL145497A0 (en)	2002-06-30
CA2372085A1 (en)	2000-11-09
ES2283298T3 (es)	2007-11-01
CA2372085C (en)	2009-10-27
KR20020013515A (ko)	2002-02-20
WO2000066604A3 (en)	2001-01-11
DK1178999T3 (da)	2007-08-06
CN1349541A (zh)	2002-05-15
CN102180924A (zh)	2011-09-14
JP2002543214A (ja)	2002-12-17
HK1048322A1 (zh)	2003-03-28
US20030087230A1 (en)	2003-05-08
US7053207B2 (en)	2006-05-30
WO2000066604A2 (en)	2000-11-09
EP1178999A2 (de)	2002-02-13
EP1178999B1 (de)	2007-03-14
KR100782896B1 (ko)	2007-12-06
NZ514348A (en)	2004-05-28
PT1178999E (pt)	2007-06-26
AU4391800A (en)	2000-11-17
AU776362B2 (en)	2004-09-09
DE60033927T2 (de)	2007-11-29

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1178999

Country of ref document: EP

2011-01-15

RZN

Patent revoked

Publication	Publication Date	Title
DE60033927D1 (de)	2007-04-26	L-ribo-lna analoge
WO2001038584A3 (en)	2001-10-25	Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
DE60041072D1 (de)	2009-01-22	Em nachweis
DK0691980T3 (da)	1997-12-29	7-deazapurinmodifiderende oligonukleotider
WO2001047944A3 (en)	2003-02-20	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE69920477D1 (de)	2004-10-28	2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind
DE69806003D1 (de)	2002-07-18	Dna polymerasen, die verbesserte fähigkeiten zum einbau markierter nukleotide besitzen
ATE416183T1 (de)	2008-12-15	Oligonukleotide mit alternierenden segmenten und deren verwendungen
AU2002365811A1 (en)	2003-06-17	Methods for the selection and cloning of nucleic acid molecules free of unwanted nucleotide sequence alterations
ATE239090T1 (de)	2003-05-15	Methode zum generieren von einzelsträngigen dna molekülen
ATE373671T1 (de)	2007-10-15	Aminooxy-modifizierte oligonukleotide
WO2005026184A3 (en)	2007-02-01	Synthesis and compositions of 2'-terminator nucleotides
WO2005044836A3 (de)	2007-07-19	Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
WO2004048397A3 (en)	2004-07-01	Detectable labeled nucleoside analogs and methods of use thereof
ID24781A (id)	2000-08-10	Proses untuk memproduksi nukleotida purin
AU2002305073A1 (en)	2002-10-08	Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
DE69815370D1 (de)	2003-07-10	Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
AU2001259131A1 (en)	2001-11-07	Detection of nucleotide sequence variations via the proofreading activity of polymerases
EP1466013A4 (de)	2006-09-06	Nukleinsäurepolymerasen aus thermus scotoductus
AU2002346517A1 (en)	2003-06-17	Thermus oshimai nucleic acid polymerases
MXPA05008817A (es)	2005-10-18	Derivados de esteres lipidos de nucleotidos.
WO2001040521A3 (en)	2002-05-16	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001048245A3 (en)	2002-11-28	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1577318A4 (de)	2008-07-02	Nukleotidderivate und dna-mikroarray
ATE311477T1 (de)	2005-12-15	Hohe dichte markierung von dns mit modifizierte oder chromophore tragende nukleotide und benutzte dns polymerasen